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Plain English summary 
Sudden cardiac death (SCD) is the sudden and unexpected death of a person, caused by a 
problem with their heart. A number of conditions can cause SCD. In people under 35 years, 
SCD is often caused by a thickening of the heart muscle (cardiomyopathy) or an electrical 
problem with the heart (for example, long QT syndrome). As people get older, SCD is more 
likely to be caused by narrowing of the blood vessels that supply the heart (coronary artery 
disease).  
 
Screening has been proposed by some people as a way to prevent sudden cardiac death in 
young people (12-39 years). The way this might work is by identifying heart conditions at an 
early stage before they cause symptoms. This would allow treatment to start earlier, which 
might prevent SCD. Other people think that screening would not be effective and may 
cause harm through unnecessary tests and treatments.  
 
Common ways to identify these conditions include:  
• asking individuals about specific symptoms and family history (medical history)  
• recording blood pressure, pulses, and listening to the heart (physical 
examination) 
• recording an electrical tracing of the heart (electrocardiogram)  
 
The UK National Screening Committee (UK NSC) last looked at the evidence for screening 
for SCD in the young in 2014. The report concluded that there was not enough evidence to 
support screening. This was because:  
• there were uncertainties on how many young people each year were affected 
by sudden cardiac death 
• it was unclear whether the tests could accurately detect heart conditions in 
young people without symptoms 
• there was no research that testing young people reduced the chance of a 
sudden cardiac death 
 
This evidence summary updates the previous UK NSC review and examines all new 
evidence published since 2014. The focus of this review is on screening of individuals in the 
general population without symptoms. It does not consider the role of screening in special 
groups, such as athletes or individuals with symptoms.  
 
The main conclusions of this review are:  
• sudden cardiac death is an important health condition 
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• research shows that current tests are not accurate enough to use in young 
people without symptoms 
• there was no research showing that screening reduces the chance of a sudden 
cardiac death in the general population  
 
Therefore, the UK NSC still cannot recommend population screening for sudden cardiac 
death in the young. Further research is necessary to understand whether screening is 
effective. However, before researchers can do a research trial of screening, there is a need 
for accurate screening tests and clear guidelines to enable clinicians to treat patients that 
have a disease, but do not have symptoms.  
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Executive summary 
Purpose of the review 
This rapid review on sudden cardiac death (SCD) in the young provides an update to the 
previous UK National Screening Committee (UK NSC) review published in 2014. The 
current review assesses the quality and volume of evidence published since 2014 on the 
incidence of SCD (since 2008 for UK studies), on the accuracy of screening tests and on 
the effectiveness of screening.  
 
 
Background 
Sudden cardiac death describes the unexpected death of an individual due to a cardiac 
cause where the death occurs soon after symptoms start (within one hour) or they are 
found dead having had no symptoms 24-hours previously. In the young individual (aged 12-
39), SCD can be caused by a range of cardiac conditions, including cardiomyopathy, 
channelopathies, and coronary artery disease. The risk of SCD varies by condition, as does 
the diagnostic process and treatment strategies.  
 
The intention of screening for SCD is to detect an underlying cardiac condition, which, 
through the initiation of early treatment, reduces the likelihood of sudden cardiac death. 
Potential treatment options include lifestyle changes, drug therapy, and insertion of an 
implantable cardioverter defibrillator. Standard strategies for screening include a physical 
assessment and medical history, which may be supplemented by an electrocardiogram 
(ECG).  
 
The American Heart Association and European Society of Cardiology do not currently 
support screening the general population for sudden cardiac death, but do support its use in 
athletes. In relation to athletic screening, there is currently a lack of international consensus 
regarding the use of the ECG in a screening setting.  
 
 
Focus of the review 
This evidence summary updates the 2014 UK NSC review by assessing relevant evidence 
published since 2014.  
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The review sought to answer 3 specific questions, which relate to criteria set out by the UK 
NSC to determine if a screening programme should be implemented in the UK: 
 
1. What is the reported incidence of sudden cardiac death (SCD) in young individuals aged 12 to 
39 years old in the UK? (Question 1 – Criterion 1) 
2. In young individuals aged 12 to 39 years old, what is the accuracy of: history-taking; physical 
examination; 12-lead electrocardiogram (ECG); mobile health devices such as mobile phones, 
tablets, smart watches and other wearables; and genetic testing as screening tools, alone or in 
combination, to identify risk of sudden cardiac death? (Question 2 – Criterion 4) 
3. What is the effectiveness of screening to prevent sudden cardiac death (SCD) in young 
individuals aged 12 to 39 years old compared to no screening? (Question 3 – Criteria 11 and 
13) 
 
The focus of this review is limited to screening of a general population of asymptomatic 
young individuals. Screening of symptomatic individuals and athletes is outside the scope 
of this review. However, where appropriate, the reviewers included evidence from studies of 
athletes, whilst acknowledging the limitations of using such indirect evidence. 
 
 
Recommendation under review 
The current UK NSC recommendation is that systematic population screening for SCD in 
the young is not recommended in the UK.  
 
In 2014, the UK NSC review on sudden cardiac death in the young concluded that there 
were insufficient data to demonstrate that key criteria had been met. In particular, it was 
reported that there was uncertainty regarding the incidence of SCD and the accuracy of 
screening tests. The review authors also found no relevant studies that evaluated the effect 
of screening by comparing outcomes in screened and non-screened individuals.  
 
 
Findings and gaps in the evidence of this review 
The current evidence summary identified 15 studies that met the inclusion criteria for 
question 1, 18 studies for question 2, and no studies for question 3.  
 
Criterion 1: The condition should be an important health problem as judged by its frequency 
and/or severity. The epidemiology, incidence, prevalence and natural history of the 
condition should be understood, including development from latent to declared disease 
and/or there should be robust evidence about the association between the risk or disease 
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marker and serious or treatable disease. Severity: MET. Incidence: NOT MET. Natural 
History: NOT CONSIDERED 
 
The authors of this review assessed the first part of criterion 1 to be met. Sudden cardiac 
death causes premature death in, seemingly, healthy young individuals, so it is an 
important health problem based on its severity. There continues to be uncertainty as to the 
true incidence of SCD, although most studies in the general population reported an 
incidence of between 1 and 2 cases per 100,000 person-years. Incidence is higher in males 
and increases with age within the 12-39 age range. Data on the potential impact of athletic 
status on incidence is inconsistent. Limited data precluded the reviewers from drawing 
conclusions regarding incidence of sudden cardiac arrest (SCA) or effect of race on 
incidence.  
 
The authors did not review data related to the second part of criterion 1, namely that the 
“natural history of the condition should be understood, including development from latent to 
declared disease and/or there should be robust evidence about the association between 
the risk or disease marker and serious or treatable disease”. On this basis, the reviewers 
are unable to comment on whether this component of the criterion is met. 
 
 
Criterion 4: There should be a simple, safe, precise and validated screening test. NOT MET 
 
This criterion was not met. For the target condition of SCD, data were available from a 
single study for one testing strategy. Whilst specificity and negative predictive value (NPV) 
were good, sensitivity and positive predictive value (PPV) were extremely low.  
 
To detect conditions that may lead to SCD as a group, the reviewers examined 7 testing 
strategies. Due to the failure to follow-up screen-test negative individuals, only PPV could 
be reported for almost all studies. Across the 44 PPVs calculated, only 3 exceeded 10%. 
The precision of the estimates for PPV was low. This means that the screening test would 
cause many individuals to be incorrectly told that they have a heart problem, which may 
cause anxiety and increase demand on secondary care cardiology services.  
 
Only data from athletic populations were identified for this question, creating concerns 
regarding the applicability of these data to the general population and highlighting the need 
for further research.  
 
 
Criterion 11: There should be evidence from high quality randomised controlled trials that 
the screening programme is effective in reducing mortality or morbidity. Where screening is 
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aimed solely at providing information to allow the person being screened to make an 
“informed choice” (eg. Down’s syndrome, cystic fibrosis carrier screening), there must be 
evidence from high quality trials that the test accurately measures risk. The information that 
is provided about the test and its outcome must be of value and readily understood by the 
individual being screened. NOT MET 
Criterion 13: The benefit gained by individuals from the screening programme should 
outweigh any harms for example from overdiagnosis, overtreatment, false positives, false 
reassurance, uncertain findings and complications. NOT MET 
 
No studies were found that were relevant to question 3 and met the inclusion criteria. A 
linked evidence approach is a way of using non-direct evidence to determine whether a 
criterion has been met. The authors of this review used relevant European Society of 
Cardiology guidelines to determine if evidence-based strategies exist for treating 
asymptomatic individuals diagnosed with a condition that may cause SCD. This is important 
as such treatment strategies are necessary for a screening programme to be effective. 
Treatment strategies for asymptomatic individuals were identified, but the evidence quality 
supporting these guideline statements was often low and it was unclear how applicable 
these guidelines were to a general population. Uncertainties remain as to the impact of 
overdiagnosis of clinically insignificant disease in the general population, and whether this 
might lead to overtreatment, such as the unnecessary cessation of sporting activity, which 
in turn can be detrimental to the overall health of young individuals.  
 
 
Recommendations on screening 
Based on the evidence identified in this review, key criteria for the implementation of a 
screening programme remain unmet. Therefore, the current evidence does not support a 
change to the current recommendation against the introduction of a systematic population 
screening programme for sudden cardiac death in the young in the UK.  
 
Limitations 
This review has 3 key limitations. Firstly, in line with UK NSC standard practice, a rapid 
review methodology was used to review evidence published since 2014. This approach 
may increase the risk that key publications are missed during the evidence selection 
process. Secondly, risk of bias in included studies means that there continues to be 
uncertainty as to the true incidence of SCD and test accuracy of screening tests. In 
particular, the assessment of question 2 on test accuracy was significantly limited by 
incomplete follow-up of screen-negative patients in studies. Thirdly, studies often focussed 
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on athletes, rather than the general population, leading to concerns regarding the 
applicability and generalisability of the evidence.  
 
 
Evidence uncertainties 
The evidence base in relation to SCD is predominantly based on screening in the young 
athlete population, rather than the general population. Key areas of uncertainties, some of 
which were described in the previous 2014 review, were identified in relation to each 
question. More research is needed to address these uncertainties.  
 
Areas of uncertainty: 
 
Question 1: 
• Evidence as to the precise incidence of sudden cardiac death in the UK 
 
Question 2: 
• Evidence to determine the test accuracy of screening tests for SCD in the 
general population 
 
Question 3: 
• Development of specific evidence-based guidelines to describe the treatment 
and lifestyle advice that should be offered to asymptomatic individuals and their 
families with a diagnosis of a condition that may cause SCD  
• Evidence on the potential lifelong impact of screening on individuals and 
families 
• Evidence relating to the effect of offering screening, compared with not offering, 
on key clinical outcomes, including incidence of SCD and potential harms, such 
as overtreatment. This evidence should ideally come from a randomised 
controlled trial. However, before a randomised controlled trial is undertaken, 
there is need to ensure that screening tests are sufficiently accurate and there 
are evidence-based guidelines that describe the effective management of 
asymptomatic individuals with a diagnosed disease 
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Introduction and approach 
Background 
The death of a young person is a tragic event, even more so when that death is sudden and 
unexpected. Cardiac death is one cause of sudden and unexpected death in young people. 
Sudden cardiac death (SCD) is defined by the American Heart Association as: 
“Sudden and unexpected death occurring within an hour of the onset of symptoms, 
or occurring in patients found dead within 24 h of being asymptomatic and 
presumably due to a cardiac arrhythmia or hemodynamic catastrophe.”(p e280)(1)  
 
The nature of SCD means that its diagnosis requires an autopsy and may result from the 
exclusion of other causes. Therefore, the accurate diagnosis of SCD can be challenging.  
 
The screening process for SCD aims to identify the range of cardiovascular conditions that 
may lead to sudden cardiac death. These conditions typically affect either the heart’s 
structure or the heart’s electrical conduction pathways (example conditions shown in table 
1). Treatments for these conditions include: ongoing monitoring, lifestyle changes (e.g. 
avoidance of sport), drug therapy, an implantable cardioverter defibrillator, and surgery.(1, 
2) Across these conditions, there are marked differences in prevalence, disease trajectory, 
treatment options and risk of sudden cardiac death.(3, 4) 
 
The conditions listed in table 1 may lead to the heart suddenly stopping (a cardiac arrest). 
In the UK, overall survival to hospital discharge following an out-of-hospital cardiac arrest is 
less than 10%.(5) The mainstay of cardiac arrest treatment is the delivery of chest 
compressions and defibrillation (electrical shocks to the heart). Short delays in the initiation 
of these treatments significantly reduce the likelihood of survival.(6-8) In situations where 
the patient suddenly collapses and treatment is started immediately, high survival rates 
have been reported.(9, 10) For example, a survival rate of 100% (n=28) was reported in 
patients with witnessed cardiac arrests at Japanese marathons over 13-year period.(10) In 
the context of SCD, a key challenge is that around one-third of events happen during sleep, 
thereby limiting the opportunity for prompt identification and treatment of cardiac arrest.(11-
14)  
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Table 1: Example conditions that may cause sudden cardiac death 
Conditions affecting the structure of the heart: 
Coronary Artery Disease 
Dilated Cardiomyopathy 
Hypertrophic cardiomyopathy 
Marfan Syndrome 
Arrhythmogenic cardiomyopathy  
Myocarditis 
Aortic dissection 
 
Conditions affecting the electrical conduction pathway: 
Brugada syndrome 
Catecholaminergic Polymorphic Ventricular Tachycardia 
Short QT syndrome 
Long QT Syndrome 
Wolff-Parkinson-White Syndrome (WPW) 
 
 
Young people with conditions that cause SCD may be asymptomatic or experience only 
vague and non-specific symptoms.(3) On this basis, the concept of screening for these 
conditions seems attractive, inasmuch as the early identification of conditions may facilitate 
early intervention and reduce the associated risk of sudden cardiac death. As such, the key 
objective of screening is to identify cardiac disease, rather than sudden cardiac death. The 
screening process typically consists of up to 3 components: medical history, physical 
examination, and resting ECG. There are a number of potential harms from screening that 
may impact individuals and their families, such as anxiety or reluctance to engage in 
sporting activity.  
 
For physical examination and medical history, the American Heart Association has 
developed a 14-point checklist, which captures elements such as recent symptoms, family 
history of sudden cardiac death or cardiovascular conditions, blood pressure recordings 
and detection of heart murmurs.(15) Following recording of an ECG (tracing of the heart’s 
electrical activity), there are a number of criteria that can be used to determine if an 
individual requires further testing. The most commonly used are the European Society of 
Cardiology criteria and the Seattle criteria.(16, 17) Importantly, however, these criteria were 
developed to be applied in the context of pre-participation screening in athletes.  
 
Individuals that are designated as screen-test positive will typically require review by a 
cardiologist and further investigations to either confirm or rule-out disease. The nature of 
these tests will depend on the results of the screening test. For example, in a study of UK 
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footballers, patients with T-wave inversion on the ECG underwent 3 further investigations, 
namely a cardiac stress test, a cardiac magnetic resonance imaging scan, and 24-hour 
monitoring of the ECG.(18) In some situations where an abnormality was identified that did 
not meet disease criteria, annual and biannual follow-up investigations were recommended.  
 
International interest in the screening for SCD in the young was initially driven by the results 
of an Italian study published in 2006 which examined the impact of the implementation of 
pre-participation screening programme for athletes aged 12-35 years in the Italian region of 
Veneto.(19) The study examined the incidence of SCD over a period of 25-years (3 years 
pre-screening; 22 years post-screening). Compared to the pre-screening period (1979–
1981), incidence of SCD in the period 1993–2004 was lower (1979–1981: 4.19 events per 
100,000 person-years [95% confidence interval (CI), 1.78–7.59)] v 1993–2004: 0.87 events 
per 100,000 person-years (95% CI, 0.46–1.28), relative risk 0.21, 95% CI 0.09–0.48). 
Approximately 2% of athletes screened were excluded from sport. In the non-athlete 
population that was not subjected to screening, there was no change in incidence of SCD 
between these periods (risk ratio 1.05, 95% CI 0.69–1.64).  
 
Aside from the before-after study design with its inherent risk of bias, a key concern 
expressed about the Italian study is the high baseline incidence of SCD (4.19 per 100,000 
person-years).(20, 21) The high initial incidence likely results from random annual variation 
in a condition with a low overall incidence, and therefore the results may simply be driven 
by bias resulting from regression to the mean. Other commentators have noted the lack of 
published follow-up data, since the original publication in 2006.(21, 22) The findings from 
the Italian study have not been replicated elsewhere.(23) 
 
International guidelines do not currently support the screening of the general asymptomatic 
population. In 2015, the European Society of Cardiology decision to not support population-
based screening for SCD was driven by concerns as to limited evidence on test accuracy 
and the relative advantages and disadvantages of screening.(2) The American Heart 
Association similarly does not support mass screening.(24) 
 
However, the European Society of Cardiology, Canadian Cardiovascular Society, and 
American Heart Association do support pre-participation screening in competitive 
athletes.(2, 24, 25) The European Society of Cardiology based this on a reported increased 
risk of SCD in this population, and the opportunity to reduce that risk through avoidance of 
competitive sport.(2) The Society advocates the use of physical examination, medical 
history and 12-lead ECG as core components of screening in athletes. In contrast, whilst 
supporting screening, both the American Heart Association and Canadian Cardiovascular 
Society recommend against the routine use of the 12-lead ECG as a screening tool.(24, 25) 
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The implementation of these guidelines in practice is variable, both within and between 
countries.(2, 24-28) For example, a survey of 257 American National Collegiate Athletic 
Association universities identified that whilst all undertook screening, screening practice 
met American Heart Association standards in only 8% of universities.(28) In screening 
programmes that incorporate an ECG, there is variability both in the criteria used to analyse 
the ECG and the expertise of the clinician that reviews it.(29, 30) These factors may impact 
the number of individuals classed as screen-test positive and therefore affect test 
performance and corresponding effectiveness and cost-effectiveness of screening.(30, 31) 
 
A key requirement for any screening programme to be effective is the willingness of the 
target population to attend screening.(32) For other adult screening programmes in the UK, 
uptake figures range from 59% (bowel cancer) to 82% (diabetes eye examination).(33) 
There are relatively few data on SCD screening programme uptake, as most papers 
describe mandatory programmes, where the individual must be screened to participate in 
sporting activity. A Spanish screening programme across 4 high schools over 8 years 
reported a screening uptake of 79%, but uptake varied markedly by year with 92% 
screened in year 1 and 61% screened in year 6.(34) An American study of 32,561 students 
at 24 high schools reported an overall uptake rate of 56%, although this varied between 
18% and 85% across schools.(35) However, the authors did note that some students may 
have received a similar examination from their own doctor.  
 
The scope of this review does not cover symptomatic patients and patients with specific 
clinical characteristics. For individuals that experience a transient loss of consciousness, for 
example, National Institute of Health and Care Excellence (NICE) guidance recommends 
assessment with a 12-lead ECG.(36) Similarly, national and international organisations 
recommend cascade screening in first-degree relatives of individuals that died due to a 
SCD or who have certain cardiac diagnoses.(1, 2, 37) 
 
 
Current policy context and previous reviews 
The previous UK NSC review on sudden cardiac death in the young was published in 
2014.(38) The review, which addressed one main, and 5 subsidiary questions, included 73 
studies. The reviewers noted challenges in interpreting data due to the limited volume of 
peer-reviewed studies. The review concluded that there was uncertainty as to the true 
incidence of SCD, absence of evidence of diagnostic test accuracy to identify SCD, and 
absence of evidence of the effectiveness of screening programmes. The evidence 
examined in the 2014 review informed the current recommendation from the UK NSC that 
systematic population screening for SCD should not be offered. 
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In 2015, the Belgian Healthcare Knowledge Centre commissioned a report which examined 
pre-participation screening in athletes.(3) Parts of the report drew on the UK NSC 
report.(38) The Belgian report concluded that there was uncertainty as to the clinical benefit 
of screening for SCD in young athletes, particularly given concerns over the accuracy of 
screening and the potential for overdiagnosis and overtreatment in cases which would 
never have become symptomatic.(3) 
 
In line with UK NSC practice for re-appraisal of evidence on screening programmes, this 
review will provide a timely update on the 2014 review on sudden cardiac death in the 
young.  
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Objectives 
The objectives of this review are: 
• To provide an update on the previous UK NSC review on SCD which reported 
in 2014,  
• To summarise recent literature on the incidence of SCD and SCA (Question 1),  
• To summarise recent literature on the accuracy of tests that may be used to 
screen for SCD or the range of conditions that may cause SCD (Question 2),  
• To summarise recent literature on the effectiveness of screening for SCD and 
estimate the effect of SCD screening on mortality, morbidity, and other key 
clinical outcomes, including harm associated with overtreatment (Question 3).  
 
Table 2 shows how these objectives link to UK NSC screening criteria, and the number of 
studies that were included for each question.  
 
Table 2. Key questions for the evidence summary, and relationship to UK NSC screening 
criteria 
 
Criterion  Key questions Studies Included  
 THE CONDITION   
1 The condition should be an important 
health problem as judged by its 
frequency and/or severity. The 
epidemiology, incidence, prevalence 
and natural history of the condition 
should be understood, including 
development from latent to declared 
disease and/or there should be robust 
evidence about the association 
between the risk or disease marker and 
serious or treatable disease.  
What is the reported 
incidence of sudden 
cardiac death (SCD) in 
young individuals aged 12 
to 39 years old in the UK? 
(Question 1) 
15 
 THE TEST   
4 There should be a simple, safe, precise 
and validated screening test.  
In young individuals aged 
12 to 39 years old, what is 
the accuracy of: 
• history-taking; 
• physical examination; 
• 12-lead 
electrocardiogram (ECG); 
and 
• mobile health devices 
such as mobile phones, 
tablets, smart watches 
and other wearables 
• genetic testing 
 
18 
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Criterion  Key questions Studies Included  
as screening tools, alone 
or in combination, to 
identify risk of sudden 
cardiac death? 
(Question 2) 
 THE SCREENING PROGRAMME   
11 There should be evidence from high 
quality randomised controlled trials that 
the screening programme is effective in 
reducing mortality or morbidity. Where 
screening is aimed solely at providing 
information to allow the person being 
screened to make an “informed choice” 
(eg. Down’s syndrome, cystic fibrosis 
carrier screening), there must be 
evidence from high quality trials that 
the test accurately measures risk. The 
information that is provided about the 
test and its outcome must be of value 
and readily understood by the 
individual being screened. 
What is the effectiveness 
of screening to prevent 
sudden cardiac death 
(SCD) in young 
individuals aged 12 to 39 
years old compared to no 
screening? (Question 3) 
0 
13 The benefit gained by individuals from 
the screening programme should 
outweigh any harms for example from 
overdiagnosis, overtreatment, false 
positives, false reassurance, uncertain 
findings and complications. 
As above As above  
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Methods 
The current review was conducted by the University of Warwick and led by Dr Keith 
Couper, in keeping with the UK National Screening Committee evidence review process. 
The review team comprised methodologists, clinical academics, and an information 
scientist. Database searches were conducted in December 2018 to identify studies relevant 
to the questions detailed in table 2. 
 
 
Eligibility for inclusion in the review  
On completion of database searches, results were imported into Endnote software and 
duplicates were removed.  
 
The following review process was then followed: 
1. A single reviewer screened each title and abstract against the inclusion/exclusion 
criteria. Where the applicability of the inclusion criteria was unclear, the article was 
included at this stage in order to ensure that all potentially relevant studies were 
captured. A second reviewer provided input in cases of uncertainty, and 
independently assessed 20% of citations. Any disagreements were resolved by 
discussion until a consensus was met. 
2. Full-text articles required for the full-text review stage were acquired. 
3. A single reviewer assessed the eligibility of the full-text paper against the 
inclusion/exclusion criteria and determined whether the article was relevant to the 
review question. A second independent reviewer provided input in cases of 
uncertainty and validated 20% of the first reviewer’s screening decisions. Any 
disagreements were resolved by discussion until a consensus was met. 
 
Eligibility criteria for each question are presented in table 3. 
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Table 3: Inclusion and exclusion criteria for the key questions 
Key 
question 
Inclusion criteria Exclusion 
criteria 
Population Target 
condition 
Intervention Reference 
Standard 
Comparator Outcome Study type  
1 
 
 
Young 
individuals 
aged 12-39 
SCD, 
SCA 
- - - Incidence Cohort 
studies and 
systematic 
reviews of 
cohort 
studies 
Non-English 
language; 
Published 
prior to 
2014 (prior 
to 2008 for 
UK studies);  
Population 
not 
comparable 
to UK (i.e. 
not 
European, 
North 
American or 
Australasian 
study); 
Published 
as abstract 
only 
2 Young 
individuals 
aged 12-39 
SCD; 
Spectrum 
of 
diseases 
that lead 
to SCD 
Screening by 
History-taking; 
Physical 
examination; 
Electrocardiogram; 
Mobile health 
Autopsy reports; 
any recognised 
reference 
standard reported 
in the paper 
appropriate for 
- Sensitivity; 
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Appraisal for quality/risk of bias tool 
The following tools were used to assess the quality and risk of bias of each study included 
in the review: 
• epidemiology studies: JBI Critical Appraisal Checklist for Studies Reporting Prevalence 
Data(39) 
• diagnostic accuracy studies: Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS-2) tool(40) 
• RCTs: Cochrane Collaboration’s “Risk of Bias” Tool(41) 
• Systematic reviews: Critical Appraisal Skills Programme checklist(42) 
 
Databases/sources searched 
An information scientist developed a specific search strategy for each review question. For 
all questions, Medline and Embase (Ovid platforms) were searched. In addition, the 
Cochrane library (Wiley interface) for question 3 was searched. Database searches were 
conducted on 5 December 2018 for question 1 and 2, and on 6 December 2018 for question 
3. Search strategies for questions 1, 2 and 3 are included as appendices 1, 4, and 7 
respectively.  
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Question level synthesis 
Criterion 1 — Incidence of sudden cardiac death 
The condition should be an important health problem as judged by its frequency and/or 
severity. The epidemiology, incidence, prevalence and natural history of the condition 
should be understood, including development from latent to declared disease and/or there 
should be robust evidence about the association between the risk or disease marker and 
serious or treatable disease.  
Question 1 – What is the reported incidence of sudden cardiac death (SCD) in young 
individuals aged 12 to 39 years old in the UK? 
 
The 2014 UK NSC review addressed the question: “how many deaths occur from sudden 
cardiac deaths in young people?” The review concluded there was uncertainty as to the 
true incidence of SCD in the young.  
 
 
Eligibility for inclusion in the review  
Cohort studies that described the incidence of SCD and SCA in young individuals aged 12-
39 years were included in this review. The key distinction between SCA and SCD is that the 
incidence of SCA will include individuals who were successfully resuscitated following 
cardiac arrest.  
 
The age range of interest was pre-defined by UK NSC. The reviewers identified variability in 
age ranges included across studies and adopted a pragmatic approach to study inclusion. 
The breakdown of SCD incidence by age reported by Risgaard et al shows that SCD 
incidence is broadly similar across the early years of life from age one to age 19, followed 
by a gradual increase to the mid-30s, beyond which point incidence increases 
markedly.(14) On this basis, studies where the population incorporated persons above 40 
years were excluded, except where the study reported a sub-group containing only 
individuals below 40. Therefore, studies of people above one year of age were included. 
Studies that included cases below the age of one were excluded due to the risk of 
conflation between SCD and sudden infant death syndrome. This approach may result in a 
small under-estimation of the overall incidence and is acknowledged as a limitation.  
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For the outcome of SCA, the reviewers only included studies where the researchers had 
sought to exclude cases which were unlikely to be attributable to SCD, for example they 
excluded cases of cardiac arrest due to trauma and asphyxia.   
 
The main reason for study exclusion at the full-text review stage (n=132) was that the study 
did not report incidence data in a relevant group. This category was used when the study 
did not report incidence data (e.g. did not relate number of cases to population at risk), 
incidence data did not cover the appropriate age category, or the study examined a 
population that was considered materially different to the UK population.  
 
Seventeen studies were excluded as they only reported cases which occurred in specific 
locations or at specific times of day, such as at school, during working hours, or whilst 
playing sport. Seven studies were excluded due to data duplication, that is data from the 
same dataset were used to answer different research questions across several 
publications. In the event of identifying studies with overlapping data, the authors of this 
evidence summary included the study with the longest recruitment period and therefore 
most cases. The exception to this were 2 Danish studies (Risgaard et al 2014; Winkel et al 
2017), where Risgaard et al was included as it provided a detailed and informative 
breakdown of incidence by age.(12, 14)  
 
Other reasons for exclusion were non-UK studies that were published between 2008 and 
2014 (n=16) and ineligible study designs, such as literature reviews (n=4).  
 
The population of interest was that of the general population aged between 12 and 39 
years. Additionally, the reviewers planned to stratify data, where possible, by age, ethnicity, 
sex, and population-type (e.g. general, non-athletes, competitive athletes, non-competitive 
athletes, elite athletes). These sub-groups are reported where data are available, but sub-
groups of sub-groups (e.g. incidence by race in athletic populations) are not considered.  
 
Data were reported as incidence per 100,000 person-years. Incidence was re-calculated 
where an alternative denominator was used. The reviewers calculated 95% confidence 
interval data, where it was not reported, and sufficient data were available, using a Poisson 
distribution in Stata version 15.1 (College Station, Texas, USA). Where necessary, data 
were extracted from graphs in papers using internet-based software (WebPlotDigitizer 
version 4.1, Austin, Texas, USA).  
 
 
Description of the evidence 
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Database searches yielded 3,943 results, of which 15 were judged to be relevant to this 
question.(11-14, 18, 23, 43-51) Search strategy is included in Appendix 1. 
 
Appendices 2 and 3 contain a full PRISMA flow diagram (Figure 1, Appendix 2) and a table 
summarising the characteristics of included publications (Table 15, Appendix 3). 
 
Of the 15 studies included, 13 reported data on the incidence of SCD, one reported 
incidence of SCA, and one reported incidence of both SCA and SCD. In the 14 studies that 
reported incidence of SCD, 2 were prospective cohort studies and 12 were retrospective 
cohort studies. The studies described populations in the UK (n=2), mainland Europe (n=6), 
USA (n=4), Canada (n=1), and Australasia (n=1).   
 
Study size varied markedly across the included studies. The smallest study reported 8 
cases of SCD, whilst the largest study reported 31,492 in a study which used death 
certificate data from across the USA over a 16-year period.(18, 49) 
 
 
Discussion of findings  
A summary of study quality, based on the Joanna Briggs Institute tool, is included in 
Appendix 3 (Table 16). The retrospective design of most studies meant the method used to 
classify SCD events was often sub-optimal, thereby increasing the risk of bias. The process 
to determine the number of SCD requires 2 stages: firstly, identification of the total number 
of deaths; and secondly, an assessment of which of these deaths meet the definition of 
SCD. In some studies, the process used to determine either the total number of deaths or 
the number of these which met SCD criteria may have led to a significant over-estimation or 
under-estimation of SCD incidence, particularly given the rarity of SCD. Most studies used 
government data to determine the number of events, which is likely to be an accurate 
estimate of the number of deaths. However, 3 studies relied on reporting of deaths by 
sports teams or identified deaths through internet searches of newspaper articles.(18, 47, 
48) This approach will likely under-estimate the incidence of SCD as it is unlikely that all 
deaths will be identified.  
 
The process of determining whether a death met the definition of SCD was similarly 
problematic. Most studies used detailed expert review of case history and autopsy reports 
to classify SCDs, which is likely to be the most effective way to diagnose sudden cardiac 
death. A key challenge in this approach is that despite most countries requiring autopsies in 
the event of sudden death, the autopsy rate reported across studies ranged from all cases 
to less than half of cases.(11, 46) Furthermore, diagnosis of SCD in cases where the cause 
of death is not structural disease (for example, a channelopathy) may be challenging and is 
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typically a diagnosis of exclusion, therefore requiring a high-quality autopsy and 
experienced pathologist. Three studies(44, 46, 49) used ICD-10 codes from death 
certificates to identify cases of SCD. This approach is likely to over-estimate the number of 
sudden cardiac deaths as whilst it considers the cause of death, it does not consider the 
circumstances surrounding the death, which are important in determining whether an event 
meets the definition of SCD. A previous study demonstrated that this approach significantly 
over-estimates the true number of sudden cardiac death cases.(52) 
 
 
Sudden cardiac death 
Incidence in the general population was reported in 11 studies (Table 4). Across these 
studies, reported incidence ranged from 1.01 to 2.89 per 100,000 person-years, with most 
studies (n=7) reporting an incidence of between one and 2 cases per 100,000 person-
years. Of the remaining 4 studies, 2 were Danish studies with some overlap in population. 
However, the precision of these estimates varied markedly between studies.  
 
A single UK study reported incidence of SCD in the general population.(44) Across the 1–
34 years age group, the reported incidence was 1.78 (95% CI, 1.61–1.96) per 100,000 
person-years. However, a key limitation to this study is that it determined cases of SCD 
using death certificate analysis. This approach may lead to an over-estimation of the true 
incidence as it does not consider the circumstances of the death, which are an essential 
component of the definition of SCD.  
 
Tables 5 to 8 show incidence across sub-groups of sex (6 studies), race (1 study), sporting 
activity (5 studies) and age (5 studies). There is consistent evidence from these studies that 
incidence of SCD is higher in males and increases with age. An American study was the 
only study to report incidence by race in the general population and reported differences 
between racial groups with the highest incidence in African-Americans. For many of these 
studies, 95% confidence intervals were not reported and not estimable from data reported 
in the paper. Where confidence intervals are reported, precision is often low.  
 
The evidence in relationship to athletic status was less clear as there was not a consistent 
relationship across studies between incidence and athletic status. Malhotra et al reported 
SCD incidence in UK adolescent footballers and reported the highest SCD incidence in any 
of the included studies of 6.8 (95% CI, 2.92–13.32) per 100,000 person-years.(18) 
However, the low absolute number of SCD events (n=8) means that the precision of this 
estimate is very low, and differences between studies could be due to design rather than 
true differences in incidence.  
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Sudden cardiac arrest 
A single included study reported on the incidence of SCA in the general population, with a 
reported incidence of 2.97 (95% CI, 2.55–3.44) per 100,000 person-years (Table 4).(51) As 
with SCD, the incidence increased with age, although this was reported in only one study 
(Table 8).  
 
Harmon et al described incidence of SCA in an athletic population, with a reported incidence of 
1.49 per 100,000 person-years (Table 7).(48) 
 
 
 
Table 4: Incidence of SCD and SCA by study across general population 
 
Study  Age Range 
Incidence per 
100,000 person-
years 
95% Confidence interval 
SUDDEN CARDIAC DEATH    
 Anastakis 2018 1-35 years 1.8 1.6–2.0 
 Astrayan 2017 10-39 years 2.89 Not estimable 
 Bagnall 2016 1-35 years 1.3 1.2–1.4 
 El-Assad 2017 1-34 years 1.32 Not estimable 
 Hofer 2014 5-39 years 1.71 1.22–2.33 
 Maron 2016 14-23 years 2.06 1.36–3.00 
 Papadakis 2009 1-34 years 1.78 1.61–1.96 
 Pilmer 2014 15-19 years 1.01 Not estimable 
 Risgaard 2014 1-35 years 2.3 2.0–2.7 
 Winkel 2017 1-35 years 2.7 2.5–2.9 
 Wisten 2017 15-35 years 1.8 1.6–1.9 
SUDDEN CARDIAC ARREST    
 Allan 2017 18-34 years 2.97 2.55–3.44 
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Table 5: Incidence of SCD and SCA by sex across general population 
 
Study  Category (sex) 
Incidence per 
100,000 person-
years 
95% Confidence interval 
SUDDEN CARDIAC DEATH    
 Bagnall 2016 Male 1.8 Not estimable 
  Female 0.7 Not estimable 
 El-Assad 2017 Male 1.79 Not estimable 
  Female 0.83 Not estimable 
 Hofer 2014 Male 2.73 Not estimable 
  Female 0.69 Not estimable 
 Pilmer 2014 Male 1.52 Not estimable 
  Female 0.47 Not estimable 
 Risgaard 2014 Male 3.2 2.6–3.8 
  Female 1.5 1.1–1.9 
 Winkel 2017 Male 3.6 3.2–3.9 
  Female 1.8 1.5–2.0 
SUDDEN CARDIAC ARREST    
 No studies    
 
 
 
 
 
Table 6: Incidence of SCD and SCA by race across general population 
 
Study  Category (race) 
Incidence per 
100,000 person-
years 
95% Confidence interval 
SUDDEN CARDIAC DEATH    
 El-Assad 2017 White 1.29 Not estimable 
  African-
American 2.4 Not estimable 
  Other 0.85 Not estimable 
  Hispanic 0.77 Not estimable 
SUDDEN CARDIAC ARREST    
 No studies    
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Table 7: Incidence of SCD and SCA by sporting activity 
 
Study  
Category 
(athletic 
status) 
Incidence per 
100,000 person-
years 
95% Confidence interval 
SUDDEN CARDIAC DEATH    
 Astrayan 2017 Non-sport 2.46 Not estimable 
  Recreational 0.43 Not estimable 
  Competitive 1.19 Not estimable 
 Harmon 2015 Competitive- Division one 2.28 1.62–3.14 
  Competitive- Division two 2.36 1.48–3.58 
  Competitive- Division three 1.15 0.69–1.80 
 Harmon 2016 Competitive 0.99 0.77–1.25 
 Malhotra 2018 Competitive 6.8 2.92–13.32 
 Maron 2016 Non-athletes 2.53 1.62–3.77 
  Athletes 0.83 0.17–2.42 
SUDDEN CARDIAC ARREST    
 Harmon 2016 Athletic 1.49 1.22–1.81 
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Table 8: Incidence of SCD and SCA by age across general population 
 
Study  Category (age in years) 
Incidence per 
100,000 person-
years 
95% Confidence interval 
SUDDEN CARDIAC DEATH    
 Bagnall 2016 11-15 0.4 Not estimable 
  16-20 1.32 Not estimable 
  21-25 1.11 Not estimable 
  26-30 1.91 Not estimable 
  31-35 3.2 Not estimable 
 El-Assad 2017 11-18 0.67 Not estimable 
  19-25 1.41 Not estimable 
  26-34 2.77 Not estimable 
 Pilmer 2014 10-14 0.54 Not estimable 
  15-19 1.01 Not estimable 
 Risgaard 2014 12-13 0.9 Not estimable 
  14-15 1.2 Not estimable 
  16-17 1.7 Not estimable 
  18-19 1.0 Not estimable 
  20-21 2.7 Not estimable 
  22-23 2.7 Not estimable 
  24-25 2.8 Not estimable 
  26-27 3.4 Not estimable 
  28-29 4.0 Not estimable 
  30-31 5.2 Not estimable 
  32-33 4.2 Not estimable 
  34-35 6.9 Not estimable 
  36-37 9.1 Not estimable 
  38-39 10.9 Not estimable 
 Winkel 2017 1-18 1.0 0.9–1.2 
  19-35 4.4 3.9–4.8 
SUDDEN CARDIAC ARREST   
 Allan 2017 2-17 0.55 0.34–0.80 
  18-34 2.97 2.55–3.44 
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Summary of Findings Relevant to Criterion 1: Severity: met. Incidence: not met. 
Natural History: not considered* 
The scope of this review was limited to the incidence of SCD and the first component of 
criterion 1, namely the importance of the health condition judged by its frequency and/or 
severity.  
 
On the basis of severity, the first part of the criterion was considered met.  
 
There continues to be uncertainty of the incidence of both SCD and SCA in the UK. 
Across included studies, key methodological weaknesses stemmed from the process 
used to determine the number and cause of deaths in a population. A single study 
reported SCD incidence in the UK general population, such that most of the evidence 
was indirect. 
 
Across studies of SCD, most reported an incidence in the range of 1 to 2 individuals per 
100,000 person-years in the general population. Incidence increases with age and is 
higher in males. Limited data makes it difficult to draw conclusions regarding incidence of 
SCA and incidence of SCD by race. Data reporting SCD incidence by athletic category 
were inconsistent.   
 
The authors of this evidence summary did not review data related to the second part of 
the criterion, namely that the “natural history of the condition should be understood, 
including development from latent to declared disease and/or there should be robust 
evidence about the association between the risk or disease marker and serious or 
treatable disease.” On this basis, the reviewers are unable to comment on whether this 
component of the criterion is met.  
 
 
 
 
 
 
                                            
 
* Met -for example, this should be applied in circumstances in which there is a sufficient volume of evidence of sufficient quality to judge an 
outcome or effect which is unlikely to be changed by further research or systematic review.  
Not Met - for example, this should be applied in circumstances where there is insufficient evidence to clearly judge an outcome or effect or 
where there is sufficient evidence of poor performance.  
Uncertain -for example, this should be applied in circumstances in which the constraints of an evidence summary prevent a reliable answer to 
the question. An example of this may be when the need for a systematic review and meta-analysis is identified by the rapid review. 
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Criterion 4 — Test accuracy  
There should be a simple, safe, precise and validated screening test.  
Question 2 –  In young individuals aged 12 to 39 years old, what is the accuracy of: 
• history-taking;  
• physical examination;   
• 12-lead electrocardiogram (ECG); and 
• mobile health devices such as mobile phones, tablets, smart watches and 
other wearables 
• genetic testing 
 
as screening tools, alone or in combination, to identify risk of sudden cardiac death? 
 
The 2014 UK NSC review addressed a similar question, namely: “what screening tests are 
available and are they reliable?” The discussion noted international variation in the tests 
used across screening programmes, and a lack of evidence on test accuracy.  
 
Eligibility for inclusion in the review  
Cohort studies, randomised controlled trials (RCTs), cross-sectional studies and systematic 
reviews of these study types were included if they evaluated the test accuracy of one or 
more key tests in relation to the target conditions of SCD or the group of conditions that 
may cause SCD in young individuals aged 12 to 39 years.   
 
Pre-defined tests of interest were: history-taking, physical examination, ECG, mobile health 
devices (e.g. mobile phones, tablets, smart watches and other wearables), genetic testing 
or a combination of these tests. Test accuracy outcomes were sensitivity, specificity, 
positive predictive value (PPV), and negative predictive value (NPV). The appropriate 
reference standard for identifying target conditions was defined as autopsy reports or any 
recognised reference standard reported in the paper and considered appropriate for the 
specific cardiac defect/abnormality under consideration.  
 
The main reason for study exclusion at the full-text review stage (n=22) was that the study 
did not report a relevant population or outcome (n=21). Specifically, 10 studies were 
excluded due to a non-relevant outcome (for example, studies that described only the 
frequency of specific ECG abnormalities), 6 studies due to population characteristics (for 
example, age group of participants or country where study was undertaken), and 5 studies 
were excluded for multiple reasons (for example, non-relevant population and non-relevant 
outcome). One study was excluded as it was a literature review (i.e. it was not a systematic 
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review). Where outcomes were not directly reported, the authors of this review derived 
outcome from data reported in the paper. Where not reported and sufficient data were 
available, 95% confidence intervals were calculated using a Poisson distribution in Stata 
version 15.1 (College Station, Texas, USA).  
 
 
Description of the evidence 
Database searches yielded 3,669 results, of which 17 were judged to be relevant to this 
question. (Appendix 4) One additional relevant article was identified through the search 
conducted for question 3, so 18 articles were ultimately included in this review.(18, 31, 53-
68)  Appendices 5 and 6 contain a full PRISMA flow diagram (Figure 2, Appendix 5) and 
tables summarising the characteristics of included publications (Tables 21–22, Appendix 6). 
 
Of the 18 included studies, there were 17 cohort studies and one systematic review. Most cohort 
studies (n=16) included only athletes. Studies were conducted across a range of countries, mainly 
USA (n=9), UK (n=3), and Australia (n=2). Sample size ranged from 330 to 419,456. Two primary 
research studies were included in both this analysis and the systematic review, on the basis that 
the systematic review did not report PPV, so there was no overlap of data.(61, 63, 66) 
 
A single study reported data on test accuracy in relation to SCD, in which the test used was 
a combination of medical history, physical examination, ECG and echocardiography.  
 
Test accuracy in relation to conditions that may cause SCD was reported in 18 studies (49 
outcomes across 7 tests). Table 9 shows the 7 tests where the reviewers were able to 
extract data across these studies, and the number of studies reporting these tests. Testing 
using an ECG was broken down according to the criteria used to assess the ECG. None of 
the included studies reported data on genetic testing or mobile/ electronic health devices. 
There was variability across studies with regard to who conducted or interpreted these 
tests.  
 
These tests are routinely performed tests in the clinical setting and are considered safe. 
Whilst simple to perform, they may require clinical expertise to interpret, particularly in the 
context of screening for sudden cardiac death.(30) 
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Table 9: Number of studies reporting each screening test (target conditions: conditions that 
may cause sudden cardiac death) 
Test  Number of studies reporting 
Medical history 10 
Physical examination  8 
ECG- European Society of Cardiology criteria 8 
ECG-  Seattle criteria 6 
ECG- other/ unknown criteria 3 
Medical history and physical examination 2 
Medical history, physical examination and ECG 12 
 
 
 
 
Discussion of findings 
A full assessment of study quality, based on the QUADAS-2 tool is included in Appendix 6 
(Tables 23-24).(40) The risk of bias was considered high in the Flow and Timing domain in 
15 out of 18 studies. There were also applicability concerns as all studies were considered 
at high risk of bias in the Patient Selection domain and 15 out of 18 studies in the Index 
Test domain. 
 
In almost all studies, the population contained only athletes, with the most common age 
range being teenage years to early 20s. Studies of athletes were eligible, as per our pre-
defined eligibility criteria. However, there were concerns regarding the applicability of these 
data to the asymptomatic general population aged 12-39 in the UK. There are documented 
differences between the hearts of athletes and non-athletes.(69-71) A screening study 
reported differences in ECG patterns between athletes and non-athletes, such that a higher 
proportion of athletes show ECG changes such as T-wave inversion and early 
repolarisation, whilst a higher proportion of non-athletes have a long corrected QT 
interval.(72) 
 
The key issue identified across almost all studies was the lack of follow-up in individuals 
who were categorised as screen-test negative. Instead, an assumption was seemingly 
made that these individuals did not have a disease that may cause SCD. As such, for these 
studies, there was no method used to determine if these individuals actually had the target 
condition, although it is acknowledged that the detailed follow-up of screen-test negative 
individuals is challenging due to the range of tests required to exclude all conditions that 
may cause sudden cardiac death. For the majority of studies, this lack of follow-up 
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precluded calculation of key outcomes, namely sensitivity, specificity, and negative 
predictive value.  
 
A systematic review, which reported data from 47,137 athletes across 15 studies was 
included.(63) However, examination of the primary research studies included in the 
systematic review indicate that these studies were at high risk of bias due to inadequate 
follow-up of screen-negative individuals. On this basis, data from the systematic review 
must be interpreted with caution.  
 
 
Sudden cardiac death 
For the outcome of SCD, a single UK-based study of adolescent footballers was 
included.(18) The screening test comprised a combination of medical history, physical 
examination, ECG and echocardiography. Screen-test positive individuals were followed-up 
and treated, where indicated, by a cardiologist. This cohort study included 11,168 
individuals, of which 830 (7.4%) were screen-test positive and 10,338 (92.6%) were screen-
test negative. Across the cohort, there were 8 (0.07%) SCD during the follow-up period. Of 
these 8 deaths, 2 (25%) were screen-test positive and 6 (75%) were screen-test negative. 
As such, the sensitivity was 25% (95% CI 3.2–65.1%), specificity was 92.6% (95% CI 92.1–
93.1%), PPV was 0.24% (95% CI 0.0–0.9%), and NPV was 99.9% (95% CI 99.9–100%). 
 
 
Conditions associated with sudden cardiac death 
In studies where the target condition was diseases that may cause SCD, sensitivity and 
specificity data could only be extracted from 2 studies. In the remaining studies, only PPV 
could be extracted due to inadequate follow-up of screen-negative individuals. For a 
number of studies, the PPV was zero, which in part reflects the small sample size and low 
incidence of the target condition.  
 
Table 10 shows outcome data across all 7 tests. Across studies for each test, there was 
marked variation in the reported PPV, although the absolute value was consistently low. In 
only 3 studies did the PPV exceed 10%. The combined test of physical examination, 
medical history and ECG was reported in 12 studies, of which one study reported a PPV 
over 10%, and no studies reported a PPV over 20%. Across all studies and tests, one study 
reported a PPV over 20% which was in relation to ECG analysed using the Seattle criteria. 
However, this was inconsistent with other studies in the category, which all reported a PPV 
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of less than 10%. The precision of the estimates for PPV, as shown by the 95% confidence 
interval, was often very low.  
 
The included systematic review reported sensitivity and specificity data for medical history 
(sensitivity 20%, specificity 94%), physical examination (sensitivity 9%, specificity 97%), 
and ECG (sensitivity 94%, specificity 93%), but, as noted above, the limitations in review 
methodology make these estimates uncertain. For the combined test of physical 
examination and medical history, Burns et al used a large insurance database (419,456 
individuals) to calculate sensitivity (44%) and specificity (96.8%).(58) However, the study 
methodology relied on a number of assumptions to categorise individuals as being screen-
test positive or screen-test negative, leading to a high risk of bias.   
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Table 10: Outcomes for screening tests (Target condition: conditions that may lead to 
sudden cardiac death) 
 
Study  Positive predictive value (%) (95% CI) Other measures 
Medical history   
 Dhutia 2016 0% (0–5.9) - 
 Drezner 2016 0.1% (0.0–0.4) - 
 Dunn 2015 0% (0–0.1) - 
 Fudge 2014 0.5% (0.1–1.7) - 
 
Harmon 2015 - 
Sensitivity 20% (95% CI, 7–44) 
Specificity 94% (95% CI, 89–
96) 
 McKinney 2017 4.1% (0.5–14.0) - 
 McKinney 2017 0% (0–14.3) - 
 Menafoglio 2014 0% (0–23.2) - 
 Price 2014 0.4% (0.0–2.3) - 
 Snoek 2015 1.3% (0.4–3.3) - 
Physical examination   
 Dhutia 2016 0% (0–18.5) - 
 Drezner 2016 0.9% (0.0–5.1) - 
 
Harmon 2015 - 
Sensitivity 9% (95% CI, 3–24) 
Specificity 97% (95% CI, 95–
98) 
 McKinney 2017 0% (0–30.9) - 
 Menafoglio 2014 0% (0–21.8) - 
 Price 2014 1.3% (0.0–7.0) - 
 Snoek 2015 11.1% (0.3–48.3) - 
ECG- European Society of Cardiology criteria  
 Brosnan 2014 1.6% (0.3–4.6) - 
 Brosnan 2014 0.9% (0.1–3.1) - 
 Dhutia 2016 3.0% (1.7–4.9) - 
 Dunn 2015 0% (0–0.9) - 
 Fudge 2014 6.9% (2.3–15.5) - 
 Menafoglio 2014 9.5% (2.7–22.6) - 
 Snoek 2015 5.0% (1.9–10.6) - 
 Wasfy 2015 0.7% (0.0–3.6) - 
ECG- Seattle criteria  
 Brosnan 2014 6.3% (1.3–7.2) - 
 Brosnan 2014 2.8% (0.3–9.9) - 
 Drezner 2016 6.8% (3.7–11.3) - 
 Dunn 2015 0 (0–3.8) - 
 Page 38 
 
Study  Positive predictive value (%) (95% CI) Other measures 
 McKinney 2017 28.6% (11.3–52.2) - 
 Wasfy 2015 8.3% (0.2–38.5) - 
ECG- Unknown/ other criteria  
 Dunn 2015 0% (0–4.6) - 
 
Harmon 2015 - 
Sensitivity 94% (95% CI, 79–
98) 
Specificity 93% (95% CI, 90–
96) 
 Price 2014 8.1% (2.7–17.8) - 
Medical history and physical examination  
 Brosnan 2014 0% (0–97.5) - 
 
Burns 2015 - 
Sensitivity 44% 
Specificity 98.6% 
(95% CIs not estimable) 
Medical history and physical examination and ECG  
 Asif 2014 2.7% (1.0–5.7) - 
 Asif 2015 3.8% (2.0–6.3) - 
 Asif 2017 7.9% (1.7–21.4) - 
 Brosnan 2014 1.6% (0.3–4.6) - 
 Dhutia 2016 2.6% (1.5–4.2) - 
 Fudge 2014 0.9% (0.3–2.2) - 
 Ghani 2016 6.5% (0.8–21.4) - 
 Malhorta 2018 5.1% (3.7–6.8) - 
 McKinney 2017 3.5% (0.4–12.1) - 
 McKinney 2017 16.7% (5.6–34.7) - 
 Menafoglio 2014 6.0% (1.7–14.6) - 
 Snoek 2015 7.3% (3.2–13.8) - 
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Summary of Findings Relevant to Criterion 4: Criterion not met† 
In view of the evidence identified, the assessment in this evidence summary is limited to 
the tests of physical examination, ECG, history-taking, and combinations of these tests.  
 
For the outcome of SCD, the single included study reported low sensitivity and extremely 
low PPV (0.2%), with an estimate that 998 out of every 1000 positive test results would 
be incorrect.  
 
For the outcome of conditions that may cause SCD, lack of follow-up in screen-test 
negative individuals in the majority of studies precluded the computation of key 
outcomes, namely sensitivity, specificity and NPV. The 2 studies that reported sensitivity 
and specificity were at high risk of bias. Across studies, very low PPVs were observed, 
which may cause unnecessary anxiety in screen-test positive individuals and their 
families and would require a large number of individuals to undergo additional testing to 
confirm or rule out disease. There was variation across studies in the criteria used to 
determine if an individual was screen-test positive, particularly in relation to ECG 
analysis. Differences in guidelines between the European Society of Cardiology and 
American Heart Association as to whether an ECG should form a routine component of 
screening in athletes highlights a lack of international consensus in screening practice.(2, 
24)  
 
Moreover, there were concerns related to the indirectness of the evidence identified. 
Almost all studies included only individuals that were athletes. In addition, ECG criteria 
used to determine screening test outcomes were specifically developed for use in 
athletes.(16, 17) Cardiological differences between athletes and non-athletes limit the 
generalisability of these data from athletes to a general population.(69-72) 
 
Overall, due to these limitations in the evidence on the accuracy and reliability of the tests 
under consideration, this criterion is not met. 
 
  
                                            
 
† Met -for example, this should be applied in circumstances in which there is a sufficient volume of evidence of sufficient quality to judge an 
outcome or effect which is unlikely to be changed by further research or systematic review.  
Not Met - for example, this should be applied in circumstances where there is insufficient evidence to clearly judge an outcome or effect or 
where there is sufficient evidence of poor performance.  
Uncertain -for example, this should be applied in circumstances in which the constraints of an evidence summary prevent a reliable answer to 
the question. An example of this may be when the need for a systematic review and meta-analysis is identified by the rapid review. 
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Criteria 11 and 13 — Effectiveness of screening   
There should be evidence from high quality randomised controlled trials that the 
screening programme is effective in reducing mortality or morbidity. Where 
screening is aimed solely at providing information to allow the person being 
screened to make an “informed choice” (eg. Down’s syndrome, cystic fibrosis carrier 
screening), there must be evidence from high quality trials that the test accurately 
measures risk. The information that is provided about the test and its outcome must 
be of value and readily understood by the individual being screened.  
 
The benefit gained by individuals from the screening programme should outweigh 
any harms for example from overdiagnosis, overtreatment, false positives, false 
reassurance, uncertain findings and complications.  
 
Question 3 –  What is the effectiveness of screening to prevent sudden cardiac death (SCD) 
in young individuals aged 12 to 39 years old compared to no screening?  
 
The 2014 UK NSC review addressed a similar question and noted that there were no 
relevant data from randomised controlled trials (RCTs) to answer this question.  
 
 
Eligibility for inclusion in the review  
The reviewers planned to include RCTs, cohort studies, and systematic reviews of cohort 
studies and RCTs that compared the effect of a screening strategy, compared with usual 
care, on clinically important outcomes. In line with current UK practice, usual care was 
defined as no offer or receipt of screening. To be eligible, we required studies to administer 
intervention and control groups at the same time. Pre-defined outcomes were: incidence of 
SCD, overall rates and types of cardiovascular pathology identified, change in any relevant 
cardiac outcome, quality of life, overdiagnosis, overtreatment, anxiety, disqualification from 
sports, and exercise avoidance.  
 
Studies published prior to 2014, non-English language papers, and studies not undertaken 
in a population comparable to the UK were excluded.  
 
The main reason for study exclusion at the full-text review stage (n=150) was that the study 
did not include a comparator group (n=105). Some of these studies had additional reasons 
for exclusion, such as a non-relevant study population. One study was excluded as it was 
not published in English (n=1). The remaining papers were non-eligible study types, namely 
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a commentary or guideline statement (n=37), abstract/ letter/ case report (n=3), or news 
article (n=3) 
 
Description of the evidence 
Database searches (Appendix 7) yielded 2,033 results, of which none were judged to be 
relevant to this question. Appendix 8 (Figure 3) contains a full PRISMA flow diagram. 
 
 
Discussion of findings  
The search identified no relevant primary research studies. 
 
On this basis, the authors of this evidence summary considered the use of a linked 
research approach in which non-direct evidence may be used to inform whether the criteria 
have been met. The following commentary is intended to be a broad overview of some 
relevant evidence, though it is not based on a systematic review of the literature.  
 
In the context of diagnostic tests, the Australian Medical Services Advisory Committee have 
devised a linked evidence approach that can be used where there is no direct evidence 
from RCTs that a diagnostic test improves patient outcome.(73) The approach addresses 4 
questions, relating to the safety of the test, the accuracy of the test, the effect of the test 
outcome on patient management, and the effect of that treatment on health outcomes.  
 
In the context of SCD, the reviewers identified in the preceding section of this report that the 
test for SCD was safe, but is not accurate. As such, a key component of the linked 
evidence approach is not met. Nevertheless, the authors considered it helpful to consider 
the final 2 components, by examining whether the earlier identification of a cardiac 
condition through screening of an asymptomatic individual would affect clinical 
management, and thereby impact patient outcome. In the 2015 Belgian review on pre-
participation screening, the authors noted that there was uncertainty regarding the benefit 
of treating asymptomatic individuals in some conditions that may cause sudden cardiac 
death.(3) 
 
In this section, the European Society of Cardiology guidelines are used to determine the 
nature of treatment that is recommended in asymptomatic individuals and the evidence 
strength supporting these recommendations.(2) The European Society of Cardiology 
guidelines were chosen, in contrast to the ones from the American Heart Association, as 
these European guidelines are more likely to inform UK cardiology practice. The European 
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Society of Cardiology categorises recommendations by a numerical category (class I, class 
II, class IIa, class IIb, class III) and letter (A, B, C). The numerical category describes the 
type of recommendation ranging from class I, where evidence shows that a treatment or 
intervention is effective, to class III, where a treatment or intervention is considered 
ineffective and/or harmful. The letter describes strength of evidence ranging from multiple 
RCTs or a meta-analysis (A) to expert opinion or retrospective/ registry studies (C).  
 
 
Hypertrophic cardiomyopathy 
European Society of Cardiology guidelines recommend the use of risk stratification in 
asymptomatic individuals with hypertrophic cardiomyopathy (I-B recommendation). The 
basis of this risk stratification stems from age, echocardiography parameters, evidence of 
non-sustained ventricular tachycardia, syncope and family history of sudden death. As 
such, even asymptomatic individuals, may be deemed to be of sufficient risk of SCD to 
benefit from an implantable cardioverter defibrillator (IIa-B recommendation). The 
guidelines also suggest an implantable cardioverter defibrillator may be considered in lower 
risk patients following a detailed assessment (IIb-B recommendation). Individuals with 
hypertrophic cardiomyopathy are advised to avoid competitive sporting activity (I-C 
recommendation).  
 
 
Dilated cardiomyopathy 
Individuals diagnosed with dilated cardiomyopathy are recommended to receive medical 
therapy to reduce the risks associated the condition (I-A recommendation). Other treatment 
recommendations are focussed on individuals with ventricular arrhythmias and/ or specific 
genetic mutations.  
 
 
Long QT syndrome 
In all individuals with long QT syndrome, European Society of Cardiology guidelines 
recommend the use of beta-blockers, avoidance of QT-prolonging medication, and 
electrolyte correction as needed (all I-B recommendations). Depending on the individual’s 
genetic mutation or QT interval, other treatments or lifestyle choices may be considered in 
asymptomatic patients (e.g. avoidance of strenuous swimming or additional drug therapy). 
The use of an implantable cardioverter defibrillator is recommended only in individuals with 
previous cardiac arrest (I-B) or syncope/ ventricular tachycardia during beta-blocker 
treatment (IIa-B).  
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Comment 
Across these 3 conditions, there are treatments that are recommended in asymptomatic 
individuals. However, the strength of evidence supporting many of these recommendations 
is categorised as grade B, indicating that is derived from large observational studies or 
individual randomised trials. This is in line with a recent analysis of European Society of 
Cardiology and American Heart Association guidelines which identified than fewer than 
15% of recommendations across all cardiology guidelines are based on level A (evidence 
from multiple RCTs) evidence.(74) In the context of European Society of Cardiology sudden 
cardiac death guidelines, 6.1% recommendations were level A, 38.9% were level B, and 
55.1% were level C. This highlights that there is some uncertainty as to the effectiveness of 
these treatment and lifestyle recommendations.  
 
There is also uncertainty around whether some of the cases of asymptomatic disease 
detected at screening would actually be overdiagnosis of disease that would not have 
become symptomatic within the person’s lifetime. This would represent harm to those 
individuals through unnecessary anxiety, medicalisation, avoidance of exercise and other 
treatments.   
 
 
Summary of Findings Relevant to Criteria 11 and 13: Criteria not met‡ 
No studies were identified that directly addressed these criteria.  
 
The use of a linked evidence approach was attempted, but noted that evidence from the 
previous question did not support the screening test being accurate. The European 
Society of Cardiology guidelines were reviewed to establish whether treatment options 
were available for asymptomatic individuals with a diagnosis of a condition that may 
cause SCD and whether such interventions were effective. Guidelines were identified that 
support the treatment of asymptomatic individuals with some diseases that may cause 
SCD. However, these recommendations were rarely underpinned by meta-analyses of 
                                            
 
‡ Met -for example, this should be applied in circumstances in which there is a sufficient volume of evidence of sufficient quality to judge an 
outcome or effect which is unlikely to be changed by further research or systematic review.  
Not Met - for example, this should be applied in circumstances where there is insufficient evidence to clearly judge an outcome or effect or 
where there is sufficient evidence of poor performance.  
Uncertain -for example, this should be applied in circumstances in which the constraints of an evidence summary prevent a reliable answer to 
the question. An example of this may be when the need for a systematic review and meta-analysis is identified by the rapid review. 
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RCTs. Moreover, there may be some uncertainty as to the effectiveness of these 
interventions, particularly in the general population.   
 
A RCT is required to answer this question, but this review indicates that there is currently 
a lack of evidence demonstrating good test accuracy and incomplete evidence around 
treatment efficacy to underpin such a trial.  
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Review Summary 
Review summary  
Conclusions and implications for policy 
This evidence summary, which updates the review published in 2014, included a total of 33 
studies across 3 research questions, thereby informing the UK NSC recommendation 
regarding the viability, effectiveness and appropriateness of a screening programme for 
sudden cardiac death in the young.  
 
Sudden cardiac death in the young is an important health problem. Most of the studies 
identified reported an incidence of SCD in individuals aged 12-39 of between one and 2 
cases per 100,000 person-years. However, there remains some uncertainty as to the true 
incidence of SCD in the general population, particularly in the UK. This review did not 
attempt to address the second part of criteria 1, namely that “the natural history of the 
condition should be understood, including development from latent to declared disease 
and/or there should be robust evidence about the association between the risk or disease 
marker and serious or treatable disease.” 
 
Studies of test accuracy in this review typically relied on an assumption that individuals in 
whom the screening test was negative did not have the disease. This precluded 
assessment of key outcomes, namely sensitivity, specificity, and negative predictive value. 
Positive predictive values for tests were typically very low. Across the 44 PPVs calculated, 
only 3 exceeded 10%. Furthermore, studies were typically undertaken in athletes, thereby 
limiting their applicability to the general population. No relevant studies were identified that 
assessed the effectiveness of screening to prevent SCD compared to no screening.  
 
This review did not specifically examine the potential short-term and long-term harms of 
screening. Low PPVs mean that a high proportion of individuals will be classed as screen-
test positive and require follow-up tests. This may lead to anxiety or a reluctance to engage 
in sporting activity, even after disease has been ruled out. Screening may create increased 
demand on secondary care services through the need for testing to rule out or confirm 
disease. There is a need for research to understand the short and long-term harms that 
may result from screening in the general population.  
 
The findings of this evidence summary are in line with current guideline statements, which 
do not support screening for SCD in the general population.(1, 2). Other reviews have 
drawn similar conclusions following a detailed review of the literature.(3) Based on such 
findings, Denmark has chosen other public health interventions focussed on reducing 
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mortality in young people (for example, response to cardiac arrest, suicide prevention, and 
reducing road traffic fatalities) over screening.(75)  
 
Screening for SCD is inevitably complex, given the need to identify a range of cardiac 
conditions that affect both the structure and electrical pathways in the heart. This is further 
complicated by a low incidence. Importantly, the assessment that key criteria were not met 
was primarily driven by a lack of peer-reviewed data that answered the pre-defined 
research questions with sufficient methodological rigour. The low PPVs reported in test 
accuracy studies are a significant cause for concern. Furthermore, the low incidence of 
SCD means that screening tests must have very high specificity to achieve acceptable 
positive predictive values.  
 
Whilst the volume of peer-reviewed studies on SCD has increased markedly since 2014, 
many of the key knowledge gaps identified were detailed in the previous UK NSC 
review.(38) There is a need for additional research: 
1. A prospective cohort study to accurately determine the incidence of SCD in the general 
population of the UK. Such a study should develop a methodology that accurately 
identifies both the total number of deaths and the number of deaths caused by sudden 
cardiac death through autopsy across the whole population, similar to that used by 
Bagnall et al.(11)  
2. Cohort studies to identify and test the optimal testing strategy for detecting SCD and 
conditions that may cause sudden cardiac death. These studies should focus on the 
general population and ensure adequate follow-up of individuals that are screen-test 
negative to enable accurate calculation of PPV, NPV, sensitivity, and specificity. The 
test would require high specificity to achieve acceptable PPV in this low incidence 
setting.  
3. Development of specific evidence-based guidelines to describe the treatment and 
lifestyle advice that should be offered to asymptomatic individuals with a diagnosis of a 
condition that may cause sudden cardiac death.  
4. Studies on the impact of screening on individuals and families, particularly those with a 
false positive result and those with a condition where there is no recommended 
treatment.  
5. A RCT to evaluate the effect of offering screening versus not offering screening on key 
clinical outcomes including incidence of SCD and potential harms, such as 
overtreatment. There may be challenges in achieving statistical power in such a study 
due to the small number of cases.  
 
Review findings do not support a change to the current recommendation against the 
introduction of a systematic population screening programme for sudden cardiac death in 
the young in the UK. 
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Limitations 
This review is subject to a number of limitations. Firstly, the methodological approach was 
that of a rapid review, as per the UK NSC standard approach. As such, database searches 
were limited by year and the reviewers did not undertake some of the strategies 
recommended by Cochrane to avoid bias and error in the selection of studies, such as the 
independent review of all titles and abstracts by 2 reviewers.(41) Whilst rapid review 
methods are accepted for this type of evidence synthesis, some rapid review approaches 
may produce differing results to systematic reviews.(76-78) In the case of this evidence 
summary, the consistency of the findings with previous reviews and international guidelines 
means that it is unlikely that the use of a rapid review methodology impacted on the overall 
conclusion.  
 
Secondly, there were challenges due to the applicability of evidence. For question 1 
(incidence of sudden cardiac death), the age range of 12-39 defined by the UK NSC 
matched few of the published studies and may not reflect current screening practice. For 
example, the screening programme delivered by Cardiac Risk in the Young in the UK 
targets individuals aged between 14 and 35 years.(79) As such, the reviewers carefully 
considered the inclusion of data from studies that included from a wider range of ages. The 
decision to include individuals in lower age groups, whilst excluding those in higher age 
groups was driven by the consistency of incidence data between the target group and 
individuals with ages outside this group.(14) This strategy may have impacted slightly on 
the reported incidence. For question 2, the focus of the data on test accuracy in athletes 
limits the generalisability of the findings to the general population.   
 
Thirdly, the risk of bias in included studies creates uncertainty as to the accuracy of the 
some of the data reported in this review. The use of validated tools to describe risk of bias 
enabled the review authors to record these issues. Nevertheless, for question 1, there were 
issues with the way that sudden cardiac deaths were identified in most studies. In addition, 
there was often insufficient data presented to enable the calculation of 95% confidence 
intervals, thereby limiting the precision of point estimates. For question 2, lack of follow-up 
in screen-test negative individuals precluded key analyses.  
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Appendix 1 — Search strategy (Question 1) 
Electronic databases 
The search strategy included searches of the databases shown in Table 11. MEDLINE, 
MEDLINE In-Process, MEDLINE Epub Ahead of Print and Embase. 
 
Table 11. Summary of electronic database searches and dates 
Database Platform Searched on date Date range of search 
MEDLINE(R) Ovid SP 5/12/18 1946 to Present 
MEDLINE(R) In-Process & Other 
Non-Indexed Citations, 
MEDLINE(R) Epub Ahead of Print 
Ovid SP 5/12/18 1946 to Present 
Embase Ovid SP 5/12/18 1980 to Present 
 
Search Terms 
Search terms included combinations of free text and subject headings (Medical Subject 
Headings [MeSH] for MEDLINE, and Emtree terms for Embase), grouped into the following 
categories: 
• disease area: Sudden cardiac death and cardiac arrest 
• outcome: Incidence 
• population: Young population and athletes 
• study design: Cohort studies and systematic reviews 
 
Search terms for MEDLINE, MEDLINE In-Process, Epub Ahead of Print and Embase are 
shown in tables 12 to 14.  
  
Table 12. Search strategy for MEDLINE 
  
Term Group # Search terms Results 
Disease area 1 Heart Arrest/ep 
[Epidemiology] 
1118 
 2 exp Death, Sudden, 
Cardiac/ep 
[Epidemiology] 
3415 
 3 Out-of-Hospital 
Cardiac Arrest/ep 
[Epidemiology] 
324 
 4 (sudden adj3 
death).tw,kw. 
37052 
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 5 (Cardiac death or 
cardiac arrest).tw,kw. 
43164 
 6 1 or 2 or 3 or 4 or 5 69342 
Outcome 7 INCIDENCE/ 236270 
 8 incidence.tw,kw. 598338 
 9 7 or 8 696122 
 10 6 and 9 8520 
Population 11 (adolescen* or young* 
or student* or athlet* 
or soccer or 
football*).tw,kw. 
948977 
 12 exp adolescent/ or 
exp adult/ or exp 
Young Adult/ or exp 
child/ 
8021644 
 13 11 or 12 8293144 
 14 10 and 13 5959 
Study design 15 cohort studies/ or 
longitudinal studies/ or 
follow-up studies/ or 
prospective studies/ 
or Retrospective 
Studies/ 
1798849 
 16 (longitudinal or 
prospective* or 
observational or 
registry).tw,kw. 
842718 
 17 (autopsy or death 
certificate*).tw,kw. 
64896 
 18 (systematic review or 
meta-analysis).kw,tw. 
153355 
 19 meta-analysis.pt. 94407 
 20 15 or 16 or 17 or 18 or 
19 
2322437 
 21 14 and 20 3764 
Limiters 22 limit 21 to (english 
language and humans 
and yr="2008 -
Current") 
2205 
 23 (letter or comment or 
editorial or case 
reports).pt. 
3236314 
 24 22 not 23 2169 
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Table 13. Search strategy for MEDLINE(R) In-Process & Other Non-Indexed Citations, 
MEDLINE(R) Epub Ahead of Print 
 
 
Term Group # Search terms Results 
Disease area 1 Heart Arrest/ep 
[Epidemiology] 
0 
 2 exp Death, Sudden, 
Cardiac/ep 
[Epidemiology] 
0 
 3 Out-of-Hospital 
Cardiac Arrest/ep 
[Epidemiology] 
0 
 4 (sudden adj3 
death).tw,kw. 
3863 
 5 (Cardiac death or 
cardiac arrest).tw,kw. 
6305 
 6 1 or 2 or 3 or 4 or 5 8275 
Outcome 7 INCIDENCE/ 0 
 8 incidence.tw,kw. 78344 
 9 7 or 8 78344 
 10 6 and 9 819 
Population 11 (adolescen* or young* 
or student* or athlet* 
or soccer or 
football*).tw,kw. 
146786 
 12 exp adolescent/ or 
exp adult/ or exp 
Young Adult/ or exp 
child/ 
1 
 13 11 or 12 146787 
 14 10 and 13 96 
Study design 15 cohort studies/ or 
longitudinal studies/ or 
follow-up studies/ or 
prospective studies/ 
or Retrospective 
Studies/ 
0 
 16 (longitudinal or 
prospective* or 
observational or 
registry).tw,kw. 
134675 
 17 (autopsy or death 
certificate*).tw,kw. 
4033 
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 18 (systematic review or 
meta-analysis).kw,tw. 
4064 
 19 meta-analysis.pt. 37 
 20 15 or 16 or 17 or 18 or 
19 
172875 
 21 14 and 20 52 
Limiters 22 limit 21 to english 
language  
52 
 
 
 
 
Table 14. Search strategy for EMBASE 
  
Term Group # Search terms Results 
Disease area 1 Heart Arrest/ep 
[Epidemiology] 828 
 2 exp Death, Sudden, 
Cardiac/ep 
[Epidemiology] 236 
 3 Out-of-Hospital 
Cardiac Arrest/ep 
[Epidemiology] 200 
 4 (sudden adj3 
death).tw,kw. 58415 
 5 (Cardiac death or 
cardiac arrest).tw,kw. 82169 
 6 1 or 2 or 3 or 4 or 5 115851 
Outcome 7 INCIDENCE/ 332649 
 8 incidence.tw,kw. 914238 
 9 7 or 8 1021184 
 10 6 and 9 14833 
Population 11 (adolescen* or young* 
or student* or athlet* 
or soccer or 
football*).tw,kw. 1339917 
 12 exp adolescent/ or 
exp adult/ or exp 
Young Adult/ or exp 
child/ 8876543 
 13 11 or 12 9330079 
 14 10 and 13 8412 
Study design 15 cohort studies/ or 
longitudinal studies/ or 1669883 
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follow-up studies/ or 
prospective studies/ 
or Retrospective 
Studies/ 
 16 (longitudinal or 
prospective* or 
observational or 
registry).tw,kw. 1438042 
 17 (autopsy or death 
certificate*).tw,kw. 78592 
 18 (systematic review or 
meta-analysis).kw,tw. 249302 
 19 15 or 16 or 17 or 18 2853450 
 20 14 and 19 3998 
Limiters 21 21. limit 20 to (human 
and english language) 3659 
 22 22. (letter or 
editorial).pt. 1593651 
 23 23. case report/ 2204788 
 24 24. 22 or 23 3596628 
 25 25. 21 not 24 3559 
 26 26. limit 25 to 
yr="2008 -Current" 2615 
 27 27. conference 
abstract.pt. 3217669 
 28 26 not 27 1722 
 
 
Results were imported into EndNote and de-duplicated. 
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Appendix 2 — Included and excluded studies 
(Question 1) 
PRISMA flowchart 
Figure 1 summarises the volume of publications included and excluded at each stage of the 
review. Fifteen publications were ultimately judged to be relevant to question 1. Reasons for 
non-inclusion of studies are summarised in the PRISMA flowchart.  
 
Figure 1: Summary of publications included and excluded at each stage for question 1
 
 
Records identified through 
database searches 
3943 
Titles and abstracts reviewed 
against eligibility criteria 
2846 
Duplicates 
1097 
Records excluded after title/abstract 
review 
2654 
Full-text articles reviewed against 
eligibility criteria 
192 Records excluded after full-text review 
176 
Does not report incidence in relevant group 
(n=132) 
Events at specific times/ locations only 
(n=17) 
Non-UK study: outside date range (n=16) 
Data overlap with other study (n=7) 
Ineligible study design (n=4) 
 Articles initially included in review 
16 
Articles selected for extraction and 
data synthesis 
15 
Articles not selected for extraction 
1 
Data inconsistencies in paper 
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Publications included after review of full-text articles 
The 15 publications included after review of full-texts are summarised in table 15 (Appendix 
3).  
 
Studies were prioritised for extraction and data synthesis. It was planned a priori that the 
following approach would be taken to prioritise studies for extraction:  
1. Systematic reviews and meta-analyses would be considered the highest quality of evidence if 
any were found.  
2. Studies would be prioritised if they considered a UK population, followed by studies from 
Western populations analogous to the UK. 
 
Of the 192 publications included after the review of titles and abstracts, 176 were ultimately 
judged not to be relevant to this review. One was excluded after an initial decision to 
include due to concerns regarding data discrepancies within the paper.(80) A list of 192 full-
text papers with reasons for inclusion and exclusion is available from the UK NSC.  
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Appendix 3 — Summary and appraisal of individual studies 
(Question 1) 
Data Extraction  
Table 15: Studies relevant to question 1 
Study/ Design Study setting/ 
recruitment period 
Population/  
Incidence 
Cases/ main causes of death  Identification of 
deaths/ events 
Ascertainment of 
SCD/ SCA 
Allan 2017(51) 
RC 
Canada (Toronto) 
2009-2012 
SCA aged 2-45 
General population 
Incidence: 2.97 per 100,000 
person-years 
178 SCA 
18-34 groups- cause of SCA: 
1) Structural myocardial disease 
32%  
2)Sudden unexplained 28% 
3)Coronary heart disease 19% 
Cardiac arrest 
registry 
Autopsy/ case data 
review by authors 
Anastasakis 
2018(50) 
RC 
Greece  
2002-2010 
SCD aged 1-35 
General population 
Incidence: 1.8 per 100,000 
person-years 
226 SCD 
Cause of death: 
1) Coronary artery disease 33% 
2) SADS 28% 
3) Vascular 19% 
Government records Autopsy/ case data 
review by authors 
Asatryan 
2017(23) 
RC 
Switzerland 
1999-2010 
SCD aged 10-39 
General population 
Incidence: 2.89 per 100,000 
person-years 
349 SCD 
Cause of death: 
1) CAD 19% 
2) MI 17% 
3) HCM 11% 
Government records Autopsy/ case data 
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Bagnall 2016(11) 
PC 
Australia/ New Zealand 
2010-2012 
SCD aged 1-35 
General population 
Incidence: 1.3 per 100,000 
person-years 
490 SCD 
Cause of death: 
1) Unexplained 40% 
2) CAD 24% 
3) Cardiomyopathies 16% 
Government records Autopsy/ case data 
review by authors 
El-Assad 
2017(49) 
RC 
USA 
1999-2015 
SCD aged 1-34 
General population 
Incidence: 1.32 per 100,000 
person-years 
31492 SCD 
Cause of death: 
1) Arrhythmia 24%  
2) Congenital heart disease 21% 
3) Ischaemic heart disease 20% 
Government records Death certificate 
ICD-10 code 
Harmon 2016(48) 
RC 
USA 
2007-2013 
SCD/ SCA aged 14-18 
Competitive athletes 
SCD incidence: 0.99 per 
100,000 person-years* 
SCA incidence: 1.49 per 
100,000 person-years 
69 SCD/ 104 SCA 
Cause of death: 
1) Idiopathic LVH/ cardiomyopathy 
26%  
2) Unknown 18% 
3) Myocarditis 14% 
Systematic media 
searches (Parent 
Heart Watch 
database), 
information from 
coaches, trainers 
and parents 
Autopsy/ case data 
review by authors 
Harmon 2015(47) 
RC 
USA 
2003-2013 
SCD- students 
Competitive athletes 
Incidence: 1.86 per 100,000 
person-years† 
79 SCD 
Cause of death: 
1) Structurally normal heart 25% 
2) Coronary artery anomalies 11% 
3= Myocarditis 10% 
3= CAD 10% 
Systematic media 
searches (Parent 
Heart Watch 
database), National 
Collegiate Athletic 
Association Records 
and insurance claims 
Autopsy/ case data 
review by authors 
Hofer 2014(46) 
RC 
Swizerland 
2000-2007 
SCD aged 5-39 
General population 
Incidence: 1.71 per 100,000 
person-years 
40 SCD 
Cause of death:  
1) MI 30% 
2) Cardiac arrest 15% 
3= Cardiomyopathy 13% 
Government records Death certificate 
ICD-10 code 
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3= Cardiac arrhythmias 13% 
Malhotra 
2018(18) 
PC 
1996-2016 
UK 
SCD- adolescents 
Competitive athletes 
Incidence: 6.8 per 100,000 
person-years 
8 SCD 
Cause of death: 
1) Cardiomyopathy 75%  
2= LVH 13% 
2= SADS 13% 
Voluntary reports, 
survey of football 
clubs, internet 
searches, 
cardiologist reports 
Death certificate/ 
autopsy data 
Maron 2016(45) 
RC 
2000-2014 
USA 
SCD aged 14-23 
General population 
Incidence: 2.06 per 100,000 
person-years‡ 
27 SCD 
Cause of death: 
1= Structurally normal heart 22%  
1= HCM 22%  
3) CAD 19% 
Government records Autopsy/ case data 
review 
Papadakis 
2009(44) 
RC 
2002-2005 
UK 
SCD aged 1-34 
General population 
Incidence: 1.78 per 100,000 
person-years 
1677 SCD 
Cause of death 
1) Acute MI 25%  
2= ARVC 16% 
2= Other myocardial disease 16% 
Government records Death certificate 
ICD-10 code 
Pilmer 2014(43) 
RC 
2005-2009 
Canada 
SCD aged 1-19 
General population 
Incidence (15-19 years): 
1.01 per 100,000 person-
years 
44 SCD (15-19 years) 
Cause of death (all ages) 
1) Myocarditis 25%  
2= ARVC 16% 
2= Other myocardial disease 16% 
Government records Autopsy/ case data 
review by authors 
Risgaard 
2014(14) 
RC 
2007-2009 
Denmark 
SCD aged 1-49 
General population 
Incidence (1-35 years): 2.3 
per 100,000 person-years 
728 SCD (1-35 years) 
Cause of death: 
1) Unexplained 48% 
2) CAD 15% 
3) ARVC 8% 
Government records Death certificate data 
(supplemented by 
information about 
event and autopsy) 
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Winkel 2017(12) 
RC 
2000-2009 
Denmark 
SCD aged 1-35 
General population 
Incidence (1-35 years): 2.7 
per 100,000 person-years 
635 SCD 
Cause of death: 
1) SADS (incl. unexplained)- 45%  
2) CAD- 13%  
3) Myocarditis-6% 
Government records Death certificate data 
(supplemented by 
information about 
event and autopsy) 
Wisten 2017(13) 
RC 
2000-2010 
Sweden 
SCD aged 1-35 
General population 
Incidence (15-35 years): 1.8 
per 100,000 person-years 
476 SCD (15-35 years)  
Cause of death: 
1) SADS 31%; 
2) Coronary artery disease 15%; 
3) Myocarditis 14%. 
Government records Autopsy/ case data 
review by authors 
*- calculated from reported figure of 1 per 101,082 person-years/ 1 per 67,064 person-years; †- calculated from reported figure of 1 per 53,703 person-years; ‡- 
calculated from figure one- total 27 deaths in 1,308,730 person-years 
Key: ARVC- Arrhythmogenic right ventricular cardiomyopathy CAD- Coronary artery disease; HCM- Hypertrophic cardiomyopathy; LVH- Left ventricular 
hypertrophy; MI- Myocardial Infarction; PC- prospective cohort; RC- retrospective cohort; SADS- Sudden Arrhythmic Death Syndrome; SCA- Sudden cardiac arrest; 
SCD- Sudden cardiac death 
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Appraisal for quality and risk of bias 
 
Table 16. Quality assessment of studies included in question one 
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Allan (2017) Unk Y Y Y Y N Y Y N/A 
Anastasakis (2018) Unk Y Y Y Y N Y Y N/A 
Asatryan (2017) Unk Y Y Y Y N N N N/A 
Bagnall (2016) Unk Y Y Y Y Y Y Y N/A 
El-Assaad (2017) Unk Y Y Y Y N N N N/A 
Harmon (2015) Unk Y Y Y N N N Y N/A 
Harmon (2016) Unk Y N N N N N Y N/A 
Hofer (2014) Unk Y N N Y N N Y N/A 
Malhotra (2018) Unk Y N Y N Y Y Y N/A 
Maron (2016) Unk Y N Y Y N Unk Y N/A 
Papadakis (2009) Y Y Y N Y N N Y N/A 
Pilmer (2014) Unk Y N Y Y N Y N N/A 
Risgaard (2014) Unk Y Y Y Y N Unk Y N/A 
Wisten (2017) Unk Y Y N Y N Unk Y N/A 
Winkel (2017) Unk Y Y Y Y N Unk Y N/A 
Key: Y- Yes; N- No; Unk- Unknown; N/A- Not applicable 
Full list of questions:  
1. Was the sample frame appropriate to address the target population? 
2.Were study participants sampled in an appropriate way? 
3.Was the sample size adequate? 
4.Were the study subjects and the setting described in detail? 
5.Was the data analysis conducted with sufficient coverage of the identified sample?  
6.Were valid methods used for the identification of the condition?  
7.Was the condition measured in a standard, reliable way for all participants?  
8.Was there appropriate statistical analysis? 
9.Was the response rate adequate, and if not, was the low response rate managed appropriately? 
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Appendix 4 — Search strategy (Question 2) 
Electronic databases 
The search strategy included searches of the databases shown in table 17. MEDLINE, 
MEDLINE In-Process, MEDLINE Epub Ahead of Print and Embase. 
 
Table 17. Summary of electronic database searches and dates 
Database Platform Searched on date Date range of search 
MEDLINE(R) Ovid SP 5/12/18 1946 to Present 
MEDLINE(R) In-Process & Other 
Non-Indexed Citations, 
MEDLINE(R) Epub Ahead of Print 
Ovid SP 5/12/18 1946 to Present 
Embase Ovid SP 5/12/18 1980 to Present 
 
 
Search Terms 
Search terms included combinations of free text and subject headings (Medical Subject 
Headings [MeSH] for MEDLINE, and Emtree terms for Embase), grouped into the following 
categories: 
• disease area: Sudden cardiac death and conditions that cause sudden cardiac 
death 
• population: Young population and athletes 
• outcome: Sensitivity, specificity and associated concepts 
• test interventions: Physical examination, medical history and other pre-defined 
tests.  
 
Search terms for MEDLINE, MEDLINE In-Process, Epub Ahead of Print and Embase are 
shown in tables 18 to 20.  
 
Table 18. Search strategy for MEDLINE 
  
Term Group # Search terms Results 
Disease area 1 heart arrest/ or death, 
sudden, cardiac/ or 
out-of-hospital cardiac 
arrest/ 
7914 
 2 exp brugada 
syndrome/ or exp long 
qt syndrome/ or exp 
3049 
 Page 61 
ventricular fibrillation/ 
or exp ventricular 
flutter/ 
 3 arrhythmias, cardiac/ or 
Tachycardia, 
Ventricular/ or Wolff-
Parkinson-White 
Syndrome/ 
6891 
 4 exp Heart Diseases/di, 
pc [Diagnosis, 
Prevention & Control] 
40611 
 5 exp Cardiac 
Conduction System 
Disease/ 
8130 
 6 exp Cardiomyopathies/ 12149 
 7 (channelopath* or long 
QT syndrome or 
catecholaminergic 
polymorphic ventricular 
tachycardia or brugada 
or Wolff-Parkinson-
White).tw,kw. 
2004 
 8 (cardiomyopath* or 
arrhythmogenic right 
ventricular 
cardiomyopathy).tw,kw. 
10504 
 9 ((Sudden adj2 death) 
or (cardiac arrest or 
cardiac death)).tw,kw. 
12106 
 10 ((cardiac or 
cardiovascular) adj2 
(disorder* or 
condition*)).tw,kw. 
2830 
 11 exp Myocardial 
Infarction/ 
18111 
 12 exp Coronary Disease/ 21613 
 13 (coronary adj2 
artery).tw,kw. 
22031 
 14 myocardial 
infarction.tw,tw. 
21705 
 15 1 or 2 or 3 or 4 or 5 or 
6 or 7 or 8 or 9 or 10 or 
11 or 12 or 13 or 14 
103702 
Population 16 (adolescen* or young* 
or student* or athlet* or 
soccer or 
football*).tw,kw. 
176412 
 Page 62 
 17 exp adolescent/ or exp 
adult/ or exp Young 
Adult/ or exp child/ 
1141191 
 18 16 or 17 1186936 
 19 15 and 18 62778 
Outcome 20 exp "Sensitivity and 
Specificity"/ 
109264 
 21 (specificity or sensitivity 
or accuracy).tw,kw. 
189011 
 22 ((false adj2 positive) or 
(false adj2 negative) or 
(true adj2 negative) or 
(true adj2 
positive)).tw,kw. 
8444 
 23 diagnostic odds 
ratio.tw,kw. 
682 
 24 exp Diagnostic Errors/ 14902 
 25 20 or 21 or 22 or 23 or 
24 
265720 
 26 19 and 25 10560 
Test interventions 27 exp Medical History 
Taking/ 
1842 
 28 ((history adj2 taking) or 
family history).tw. 
8661 
 29 Physical Examination/ 4365 
 30 physical exam*.tw,kw. 9064 
 31 exp 
Electrocardiography/ 
16845 
 32 (electrogardiogram or 
ECG).tw,kw. 
7353 
 33 "Monitoring, 
Ambulatory"/ 
1725 
 34 ((wearable or 
ambulatory) adj2 
(device* or 
monitor*)).tw,kw. 
1320 
 35 (genetic adj2 (test* or 
screen*)).tw,kw. 
6978 
 36 Genetic Testing/ 6508 
 37 27 or 28 or 29 or 30 or 
31 or 32 or 33 or 34 or 
35 or 36 
52917 
 38 26 and 37 2315 
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Limiters 39 limit 38 to (english 
language and humans) 
2252 
 40 (letter or comment or 
editorial or case 
reports).pt. 
446948 
 41 39 not 40 1993 
 42 limit 41 to yr="2014-
current" 
1993 
 
 
 
Table 19. Search strategy for MEDLINE(R) In-Process & Other Non-Indexed Citations, 
MEDLINE(R) Epub Ahead of Print 
 
Term Group # Search terms Results 
Disease area 1 heart arrest/ or death, 
sudden, cardiac/ or 
out-of-hospital cardiac 
arrest/ 
0 
 2 exp brugada 
syndrome/ or exp long 
qt syndrome/ or exp 
ventricular fibrillation/ 
or exp ventricular 
flutter/ 
0 
 3 arrhythmias, cardiac/ or 
Tachycardia, 
Ventricular/ or Wolff-
Parkinson-White 
Syndrome/ 
0 
 4 exp Heart Diseases/di, 
pc [Diagnosis, 
Prevention & Control] 
0 
 5 exp Cardiac 
Conduction System 
Disease/ 
0 
 6 exp Cardiomyopathies/ 0 
 7 (channelopath* or long 
QT syndrome or 
catecholaminergic 
polymorphic ventricular 
tachycardia or brugada 
or Wolff-Parkinson-
White).tw,kw. 
1552 
 8 (cardiomyopath* or 
arrhythmogenic right 
7249 
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ventricular 
cardiomyopathy).tw,kw. 
 9 ((Sudden adj2 death) 
or (cardiac arrest or 
cardiac death)).tw,kw. 
8221 
 10 ((cardiac or 
cardiovascular) adj2 
(disorder* or 
condition*)).tw,kw. 
2084 
 11 exp Myocardial 
Infarction/ 
0 
 12 exp Coronary Disease/ 0 
 13 (coronary adj2 
artery).tw,kw. 
15785 
 14 myocardial 
infarction.tw,tw. 
14552 
 15 1 or 2 or 3 or 4 or 5 or 
6 or 7 or 8 or 9 or 10 or 
11 or 12 or 13 or 14 
42194 
Population 16 (adolescen* or young* 
or student* or athlet* or 
soccer or 
football*).tw,kw. 
146874 
 17 exp adolescent/ or exp 
adult/ or exp Young 
Adult/ or exp child/ 
1 
 18 16 or 17 146875 
 19 15 and 18 2677 
Outcome 20 exp "Sensitivity and 
Specificity"/ 
0 
 21 (specificity or sensitivity 
or accuracy).tw,kw. 
166659 
 22 ((false adj2 positive) or 
(false adj2 negative) or 
(true adj2 negative) or 
(true adj2 
positive)).tw,kw. 
5538 
 23 diagnostic odds 
ratio.tw,kw. 
338 
 24 exp Diagnostic Errors/ 0 
 25 20 or 21 or 22 or 23 or 
24 
169868 
 26 19 and 25 115 
Test interventions 27 exp Medical History 
Taking/ 
0 
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 28 ((history adj2 taking) or 
family history).tw. 
7232 
 29 Physical Examination/ 0 
 30 physical exam*.tw,kw. 8080 
 31 exp 
Electrocardiography/ 
0 
 32 (electrogardiogram or 
ECG).tw,kw. 
5017 
 33 "Monitoring, 
Ambulatory"/ 
0 
 34 ((wearable or 
ambulatory) adj2 
(device* or 
monitor*)).tw,kw. 
1438 
 35 (genetic adj2 (test* or 
screen*)).tw,kw. 
5450 
 36 Genetic Testing/ 0 
 37 27 or 28 or 29 or 30 or 
31 or 32 or 33 or 34 or 
35 or 36 
25941 
 38 26 and 37 36 
Limiters 39 limit 38 to (english 
language and humans) 
36 
 40 limit 39 to yr="2014-
current" 
28 
 
 
Table 20. Search strategy for EMBASE 
  
Term Group # Search terms Results 
Disease area 1 heart arrest/ or death, 
sudden, cardiac/ or 
out-of-hospital cardiac 
arrest/ 
65256 
 2 exp brugada 
syndrome/ or exp long 
qt syndrome/ or exp 
ventricular fibrillation/ 
or exp ventricular 
flutter/ 
40863 
 3 arrhythmias, cardiac/ or 
Tachycardia, 
Ventricular/ or Wolff-
Parkinson-White 
Syndrome/ 
39448 
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 4 exp Heart Diseases/di, 
pc [Diagnosis, 
Prevention & Control] 
246973 
 5 exp Cardiac 
Conduction System 
Disease/ 
83248 
 6 exp Cardiomyopathies/ 120377 
 7 (channelopath* or long 
QT syndrome or 
catecholaminergic 
polymorphic ventricular 
tachycardia or brugada 
or Wolff-Parkinson-
White).tw,kw. 
18404 
 8 (cardiomyopath* or 
arrhythmogenic right 
ventricular 
cardiomyopathy).tw,kw. 
101676 
 9 ((Sudden adj2 death) 
or (cardiac arrest or 
cardiac death)).tw,kw. 
115068 
 10 ((cardiac or 
cardiovascular) adj2 
(disorder* or 
condition*)).tw,kw. 
22481 
 11 exp Myocardial 
Infarction/ 
329912 
 12 exp Coronary Disease/ 285695 
 13 (coronary adj2 
artery).tw,kw. 
245701 
 14 myocardial 
infarction.tw,tw. 
229053 
 15 1 or 2 or 3 or 4 or 5 or 
6 or 7 or 8 or 9 or 10 or 
11 or 12 or 13 or 14 
1061778 
Population 16 (adolescen* or young* 
or student* or athlet* or 
soccer or 
football*).tw,kw. 
1339917 
 17 exp adolescent/ or exp 
adult/ or exp Young 
Adult/ or exp child/ 
8876543 
 18 16 or 17 9330079 
 19 15 and 18 521597 
Outcome 20 exp "Sensitivity and 
Specificity"/ 
310757 
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 21 (specificity or sensitivity 
or accuracy).tw,kw. 
1466669 
 22 ((false adj2 positive) or 
(false adj2 negative) or 
(true adj2 negative) or 
(true adj2 
positive)).tw,kw. 
81533 
 23 diagnostic odds 
ratio.tw,kw. 
2058 
 24 exp diagnostic error/pc 
[Prevention] 
577 
 25 20 or 21 or 22 or 23 or 
24 
1623867 
 26 19 and 25 33243 
Test interventions 27 family history/ 95279 
 28 ((history adj taking) or 
family history).tw,kw. 
98831 
 29 Physical Examination/ 190265 
 30 physical exam*.tw,kw. 101380 
 31 exp 
Electrocardiography/ 
126914 
 32 (electrogardiogram or 
ECG).tw,kw. 
93999 
 33 "Monitoring, 
Ambulatory"/ 
10572 
 34 ((wearable or 
ambulatory) adj2 
(device* or 
monitor*)).tw,kw. 
11735 
 35 (genetic adj (test* or 
screen*)).tw,kw. 
46722 
 36 Genetic Testing/ 41499 
 37 27 or 28 or 29 or 30 or 
31 or 32 or 33 or 34 or 
35 or 36 
613896 
 38 26 and 37 7186 
Limiters 39 limit 38 to (human and 
english language and 
yr="2014 -Current") 
2452 
 40 case report/ 2204788 
 41 (letter or editorial).pt. 1593651 
 42 40 or 41 3596628 
 43 39 not 42 2241 
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 44 conference abstract.pt. 3217669 
 45 43 not 44 1648 
 
 
 
Results were imported into EndNote and de-duplicated. 
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Appendix 5 — Included and excluded studies 
(Question 2) 
PRISMA fowchart 
Figure 2 summarises the volume of publications included and excluded at each stage of the 
review. Eighteen publications were ultimately judged to be relevant to question 2. Reasons 
for non-inclusion of studies are summarised in the PRISMA flowchart.  
 
Figure 2: Summary of publications included and excluded at each stage for question 2 
 
Records identified through 
database searches 
3669 
Titles and abstracts reviewed 
against eligibility criteria 
3013 
Duplicates 
656 
Records excluded after title/abstract 
review 
2974 
Full-text articles reviewed against 
eligibility criteria 
39 
Additional articles included from other 
searches  
1 
Records excluded after full-text review 
22 
Non-relevant outcome or population (n=21) 
Literature review (n=1) 
Articles initially included in review 
18 
Articles selected for extraction and 
data synthesis 
18 
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Publications included after review of full-text articles 
The 18 publications included after review of full-texts are summarised in tables 21-22 
(Appendix 6).  
 
Studies were prioritised for extraction and data synthesis. It was planned a priori that the 
following approach would be taken to prioritise studies for extraction:  
1. Systematic reviews and meta-analyses would be considered the highest quality of evidence if 
any were found.  
2. Studies would be prioritised if they considered a UK population, followed by studies from 
Western populations analogous to the UK. 
 
Of the 39 publications included after the review of titles and abstracts, 22 were ultimately 
judged not to be relevant to this review. A list of the 39 full-text papers with reasons for 
inclusion and exclusion is available from the UK NSC.   
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Appendix 6 — Summary and appraisal of individual studies 
(Question 2) 
Data Extraction  
 
Table 21: Studies relevant to question 2 (target condition: sudden cardiac death) 
Study/ 
Design 
Study setting/ 
recruitment period 
Population Test/ 
% screen-test positive 
Screening programme Outcome 
Malhotra 
2018(18) 
Prospective 
cohort 
UK 
1996-2016 
11,168 Adolescent footballers 
Mean age 16.4 years 
95% male 
 
Medical history, physical 
examination, ECG, 
echocardiography (7.43%) 
One-off 
Results reviewed by expert 
cardiologist 
Sensitivity 25% (95% 
CI 3.2 to 65.1%) 
Specificity 92.6% 
(95% CI 92.1 to 
93.1%) 
PPV 0.24% (95% CI 
0.0 to 0.9%) 
 True +ve 2/830  
 False +ve 828/830 
NPV 99.9% (95% CI 
99.9 to 100%) 
 True –ve 6/10338 
 False –ve 
10332/10338 
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Table 22: Studies relevant to question 2 (target condition: conditions that may cause sudden cardiac death) 
Study/ 
Design 
Study setting/ 
recruitment period 
Population Test/ 
% screen-test positive 
Screening programme 
frequency/ who 
delivered 
Outcome 
Asif 2014(53) 
 
Prospective 
cohort 
 
USA 802 High school athletes 
Mean age 15.5 years 
51% male 
71.2% Caucasian/ 10.6% 
Asian 
American Heart Association 
history questionnaire 
(Medical history), physical 
examination and ECG 
(Seattle criteria) (28.18%) 
 
One-off 
Unknown 
PPV 2.65% 
 True +ve- 6/226 
 False +ve 220/226 
 
Asif 2015(54) 
 
Prospective 
cohort 
USA 1516 athletes 
Mean age 15.6 years 
59.3% male 
56.2% Caucasian/ 24.5% 
African-american or black 
American Heart Association 
history questionnaire 
(Medical history), physical 
examination and ECG 
(Seattle criteria) (22.82%) 
 
One-off 
Unknown 
PPV 3.76% 
 True +ve 13/346 
 False +ve 333/346 
Asif 2017(55) 
 
Prospective 
cohort 
 
USA 1192 athletes 
Median age 19 years 
55.4% male 
80.4% white/ 7.2% black 
Medical history, physical 
examination and ECG 
(Seattle criteria) (3.19%) 
One-off 
Unknown 
PPV 7.89% 
 True +ve- 3/38 
 False +ve 35/38 
Brosnan 
2014(56) 
 
Prospective 
cohort 
 
Australia 
2011-2012 
1078 Elite athletes 
Mean age 20 years 
82% male 
86% White/ 7% Indigenous 
Australian 
Medical history and physical 
examination (0.09%) 
 
 
 
ECG (ESC criteria) (17.25%) 
 
 
 
 
ECG (Seattle criteria) (4.45%) 
 
 
 
 
One-off 
Usually by cardiologist. All 
reviewed by cardiologist. 
 
 
One-off 
Usually by cardiologist. All 
reviewed by cardiologist. 
 
 
One-off 
Usually by cardiologist. All 
reviewed by cardiologist. 
 
 
One-off 
PPV 0% 
 True +ve- 0/1 
 False +ve 1/1 
 
 
PPV 1.61% 
 True +ve 3/186 
 False +ve 183/186 
 
 
PPV 6.25% 
 True +ve 3/48 
 False +ve 45/48 
 
 
PPV 1.60% 
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Combination (History, 
Physical and ECG) (17.35%) 
 
 
Usually by cardiologist. All 
reviewed by cardiologist. 
 
 True +ve 3/187 
 False +ve 184/187 
Brosnan 
2014(57) 
 
Prospective 
cohort 
Australia 
2011-2013 
1261 Elite athletes 
Mean age 20.6 years 
78.9% male 
86% White/ 12% Indigenous 
Australian 
ECG (ESC criteria) (18.08%) 
 
 
 
 
ECG (Seattle criteria) (5.63%) 
 
 
One-off 
Screening by 2 
experienced cardiologists 
 
 
One-off 
Screening by 2 
experienced cardiologists 
PPV 0.88% 
 True +ve- 2/228 
 False +ve 226/228 
 
 
PPV 2.82% 
 True +ve 2/71 
 False +ve 69/71 
 
Burns 
2015(58) 
 
Retrospective 
cohort 
 
USA 
2005-2009 
419,456 athletes (examination 
for sports competition) 
Mean age 14 years 
History/ physical examination 
(1.71%) 
One-off 
Unknown 
Sensitivity 44% 
Specificity 96.8% 
Dhutia 
2016(31) 
 
Prospective 
cohort 
UK 
2011-2014 
4925 athletes 
Mean age 19.9 years 
83% male 
85% White/ 9% Afro-
Caribbean 
History (1.24%) 
 
 
 
 
Physical examination (0.37%) 
 
 
 
 
ECG (modified ESC criteria) 
(10.19%) 
 
 
 
 
Combination (History, 
Physical and ECG) (11.80%) 
 
One-off 
Screening by experienced 
sports cardiologist 
 
 
One-off 
Screening by experienced 
sports cardiologist 
 
 
One-off 
Screening by experienced 
sports cardiologist 
 
 
One-off 
Screening by experienced 
sports cardiologist 
 
PPV 0% 
 True +ve 0/61 
 False +ve 61/61  
 
 
PPV 0% 
 True +ve 0/18  
 False +ve 18/18 
 
 
PPV 2.99% 
 True +ve 15/502  
 False +ve 487/502 
 
 
PPV 2.58% 
True +ve 15/581 
False +ve 566/581 
Drezner 
2016(59) 
 
Prospective 
cohort 
USA 
2012-2014 
5258 athletes 
Mean age 20.1 years 
55% male 
73% Caucasian/ 16% African-
American 
American Heart Association 
history questionnaire 
(Medical history) (33.28%)  
 
 
Physical examination (2.05%) 
 
One-off 
Unknown 
 
 
 
One-off 
Unknown 
PPV 0.1% 
 True +ve 2/1750  
 False +ve 1748/1750 
 
 
PPV 0.9% 
 True +ve 1/108 
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ECG (Seattle criteria) (3.65%) 
 
 
 
One-off 
Interpreted by cardiologist 
 False +ve 107/108 
 
 
PPV 6.8% 
 True +ve 13/192 
 False +ve 179/192 
 
Dunn 
2015(60) 
 
Prospective 
cohort 
USA 1596 athletes 
Mean age 19.7 years 
62% male 
65% White/ 19% African-
American 
American Heart Association 
history questionnaire 
(Medical history) (23.81%) 
 
 
 
 
 
ECG (ESC criteria) (26.82%) 
 
 
 
 
 
ECG (Seattle criteria) (5.95%) 
 
 
 
 
 
ECG (Stanford criteria) 
(4.89%) 
 
One-off 
Administered by medical 
staff or volunteers (follow-
up by sports medicine 
physician if positive reply) 
 
 
One-off 
ECGs reviewed for 
accuracy by an expert in 
sports cardiology 
 
 
One-off 
ECGs reviewed for 
accuracy by an expert in 
sports cardiology 
 
 
One-off 
ECGs reviewed for 
accuracy by an expert in 
sports cardiology 
PPV 0% 
 True +ve 0/380  
 False +ve 380/380 
 
 
 
 
PPV 0% 
 True +ve 0/428 
 False +ve 428/428 
 
 
 
PPV 0% 
 True +ve 0/95  
 False +ve 95/95 
 
 
 
PPV 0% 
 True +ve 0/78 
 False +ve 78/78 
 
 
Fudge 
2014(61) 
 
Prospective 
cohort 
USA 
2010-2011 
1339 Mixed population (80% 
in organised sports team) 
Age 63% aged 16-20 
49% male 
68% Caucassian/ 18% Asian 
or Pacific islander 
Medical history- self-report 
questionnaire (31.44%) 
 
 
 
 
Physical examination (9.26%) 
 
 
 
 
 
ECG (ESC criteria) (5.38%) 
 
One-off 
Physician interview 
including review of 
questionnaire 
 
 
One-off 
Blood pressure by 
firefighters. Physician 
examination/ interview 
 
 
One-off 
PPV 0.48% 
 True +ve 2/421  
 False +ve 419/421 
 
 
 
Data not reported 
 
 
 
 
 
PPV 6.94% 
 True +ve 5/72  
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Combined (History, Physical 
and ECG) (40.03%) 
Interpreted by experienced 
sports medicine or 
cardiology physician 
 
 
One-off 
As individual components 
above 
 False +ve 67/72 
 
 
 
PPV 0.93% 
 True +ve 5/536 
 False +ve 531/536 
 
Ghani 
2016(62) 
 
Prospective 
cohort 
 
 
England 
2010-2012 
1191 Elite rughby players 
Mean age 22.5 years 
100% male 
85.6% Caucassian/ 5.5% 
Afro-Carribbean 
Medical history, physical 
examination, ECG, 
echocardiography (2.85%) 
One-off 
Screening manager, 
cardiac physiologist, 
cardiology fellow 
PPV 6.45% 
 True +ve 2/31 
 False +ve 29/31 
Harmon 
2015(63) 
 
Systematic 
review and 
meta-analysis 
European countries, 
USA, Algeria, Dubai, 
Qatar 
19972-2014 
 
47,137 individuals across 15 
studies 
13 of 15 studies included only 
athletes 
Age range 5-39 
66% male 
 
Medical history 
 
 
 
Physical examination 
 
 
 
12-lead ECG 
Varied across studies 
 
 
 
Varied across studies 
 
 
 
Varied across studies 
 
Sensitivity 20%  
Specificity 94% 
 
 
Sensitivity 9% 
Specificity 97% 
 
 
Sensitivity 94% 
Specificity 93% 
 
Malhotra 
2018(18) 
 
Prospective 
cohort 
 
UK 
1996-2016 
11,168 Adolescent footballers 
Mean age 16.4 years 
95% male 
Medical history, physical 
examination, ECG, 
echocardiography (7.43%) 
One-off 
Results reviewed by expert 
cardiologist 
PPV 5.06% 
 True +ve 42/830  
 False +ve 788/830 
McKinney 
2017(64) 
 
Prospective 
cohort 
 
 
 
 
 
 
 
 
Canada 
2013-2015 
PHASE1 
680 competitive athletes 
Mean age 19.6 years 
73.7% male 
76.2% Caucasian/ 8.2% 
Asian 
 
 
 
 
 
 
 
Modified American Heart 
Association history 
questionnaire 
(Medical history) (7.21%) 
 
 
Physical examination (1.47%) 
 
 
 
 
 
One-off  
Physician present 
 
 
 
 
One-off  
Cardiologists, cardiology 
fellows, internal medicine 
residents 
 
 
One off 
PPV 4.1% 
 True +ve 2/49 
 False +ve 47/49 
 
 
 
PPV 0% 
 True +ve 0/10 
 False +ve 10/10 
 
 
 
PPV 3.51% 
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PHASE 2 
679 competitive athletes 
Mean age 20.7 years 
56.8% male 
72.6% Caucasian/ 11.0% 
Asian 
 
 
 
 
 
PHASE 1 and 2 
Mean age 1359 years 
65.3% male 
74.4% Caucasian/ 9.6% 
Asian 
 
Combination (History, 
Physical and ECG) (8.38%) 
 
 
 
 
Medical history questionnaire 
(developed by authors) 
(3.53%) 
 
 
Combined (History, ECG) 
(4.42%) 
 
 
 
 
ECG (Seattle criteria) (1.55%) 
As individual components 
above. ECG interpretation 
by cardiologist 
 
 
One-off  
Non-physicians 
 
 
 
One-off 
As history above. ECG 
interpretation by 
cardiologist 
 
 
One-off  
ECG interpretation by 
Cardiologist 
 True +ve 2/57 
 False +ve 55/57 
 
 
 
PPV 0% 
 True +ve 0/24 
 False +ve 24/24 
 
 
PPV 16.67% 
 True +ve 5/30 
 False +ve 25/30 
 
 
 
PPV 28.6% 
 True +ve 6/21 
 False +ve 15/21 
 
Menafoglio 
2014(65) 
 
Prospective 
cohort 
Switzerland 
2011-2012 
1070 competitive athletes 
Mean age 19.7 years 
75.2% male 
97.9% Caucassian 
Medical history (1.31%) 
 
 
 
 
Physical examination (1.40%) 
 
 
 
 
 
ECG (ESC criteria) (3.93%) 
 
 
 
Combination (History, 
Physical and ECG) (6.26%) 
 
 
One-off 
Cardiologist/ sports 
physician  
 
 
One-off 
Cardiologist/ sports 
physician  
 
 
One-off 
Cardiologist/ sports 
physician 
 
 
One-off 
As individual components 
above 
 
PPV 0% 
 True +ve 0/14 
 False +ve 14/14 
 
 
PPV 0% 
 True +ve 0/15 
 False +ve 15/15 
 
 
PPV 9.52% 
 True +ve 4/42 
 False +ve 38/42 
 
 
PPV 5.97% 
 True +ve 4/67 
 False +ve 63/67 
Price 
2014(66) 
 
USA 
2010-2011 
2017 High School athletes 
Age range 14-18 years 
71% male 
Medical history based on 
AHA questionnaire (12.10%) 
 
 
One-off 
Nurse 
 
 
PPV 0.41% 
 True +ve 1/244 
 False +ve 243/244 
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Prospective 
cohort 
 
34% Caucassian/ 31% Black 
or African-American 
 
Physical examination (3.82%) 
 
 
 
 
ECG (3.07%) 
 
 
 
One-off 
Unknown 
 
 
 
One-off 
Cardiac technician 
 
PPV 1.30% 
 True +ve 1/77 
 False +ve 76/77 
 
 
PPV 8.06% 
 True +ve 5/62 
 False +ve 57/62 
 
Snoek 
2015(67) 
 
Retrospective 
cohort 
 
Holland 
2011 
561 athletes/ military 
Median age 18 years 
71% male 
 
Medical history (55.26%) 
 
 
 
 
 
Physical examination (1.60%) 
 
 
 
 
 
ECG (ESC criteria) (21.39%) 
 
 
 
 
Combination (History, 
Physical and ECG) (19.61%) 
 
 
 
 
One-off 
Sports physician/ sports 
physician trainee/ physician 
assistant 
 
 
One-off 
Sports physician/ sports 
physician trainee/ physician 
assistant 
 
 
One-off 
Member of sports medicine 
and cardiology department 
 
 
One-off 
As individual components 
above 
PPV 1.29% 
 True +ve 4/310  
 False +ve 306/310 
 
 
 
PPV 11.11% 
 True +ve 1/9  
 False +ve 8/9 
 
 
 
PPV 5.00% 
 True +ve 6/120 
 False +ve 114/120 
 
 
PPV 7.27% 
 True +ve 8/110 
 False +ve 102/110 
Wasfy 
2015(68) 
 
Prospective 
Cohort 
USA 
2006-2013 
330 college rowers 
Mean age 18.9 years 
56% male 
91% Caucasian/ 3% Afro-
Caribbean 
 
ECG (ESC criteria) (46.67%) 
 
 
 
 
ECG (Seattle criteria) (3.63%) 
One-off 
Cardiologist 
 
 
 
One-off 
Cardiologist 
PPV 0.65% 
 True +ve 1/154 
 False +ve 153/154 
 
 
PPV 8.3% 
 True +ve 1/12 
 False +ve 11/12 
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Appraisal for quality and risk of bias 
Quality assessments of included studies are reported below.  
 
Table 23: Quality assessment of studies included in question 2 (target condition: sudden 
cardiac death) 
 Risk of bias Applicability concerns 
Patient 
selection 
Index 
test 
Reference 
standard 
Flow and 
timing 
Patient 
selection 
Index 
test 
Reference 
standard 
Malhotra (2018) Low Low Low Low High Low Low 
 
 
Table 24: Quality assessment of studies included in question 2 (target condition: conditions 
that may cause sudden cardiac death) 
 
 Risk of bias Applicability concerns 
Patient 
selection 
Index 
test 
Reference 
standard 
Flow and 
timing 
Patient 
selection 
Index 
test 
Reference 
standard 
Asif (2014) Low Unk Unk High High High Unk 
Asif (2015) Low Low Unk High High High Low 
Asif (2017) Low Unk Unk High High Unk Unk 
Brosnan (2014) Low Low Low High High High High 
Brosnan (2014) Low Low Unk High High High Unk 
Burns (2015) High High High High High High High 
Dhutia (2016) Low Low Low High High High Low 
Dreznor (2016) Low Low Low Unk High High Low 
Dunn (2015) Unk Low Low High High High Low 
Fudge (2014) Low Low High High High Low Low 
Ghani (2016) Unk Low Low High High High Low 
Harmon (2015) N/A N/A N/A N/A N/A N/A N/A 
Malhotra (2018) Low Low Low High High High Low 
McKinney (2017) Low Low Low High High High Low 
Menafoglio (2014) Low Low Low High High High Low 
Price (2014) Low Low Low Low High High Low 
Snoek (2015) Low Low Low High High High Low 
Wasfy (2015) Low Low Low High High High Low 
Key: Unk- Unknown; N/A- Not applicable 
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Appendix 7 — Search strategy (Question 3) 
Electronic databases 
The search strategy included searches of the databases shown in table 25. MEDLINE, 
MEDLINE In-Process, MEDLINE Epub Ahead of Print, Embase and the Cochrane Library.  
 
Table 25. Summary of electronic database searches and dates 
Database Platform Searched on date Date range of search 
MEDLINE(R) Ovid SP 6/12/18 1946 to Present 
MEDLINE(R) In-Process & Other 
Non-Indexed Citations, 
MEDLINE(R) Epub Ahead of Print 
Ovid SP 6/12/18 1946 to Present 
Embase Ovid SP 6/12/18 1980 to Present 
Cochrane Database of Systematic 
Reviews and Cochrane Central 
Register of Controlled Trials 
Wiley Online 6/12/18 Issue 12 of 12, 
December 2018 
 
 
Search terms included combinations of free text and subject headings (Medical Subject 
Headings [MeSH] for MEDLINE, and Emtree terms for Embase), grouped into the following 
categories: 
• disease area: Sudden cardiac death 
• population: Young population and athletes 
• intervention: Screening 
• study design: Randomised controlled trials, cohort studies and systematic reviews 
 
Search terms for MEDLINE, MEDLINE In-Process, Epub Ahead of Print, Embase, and 
Cochrane Library are shown in tables 26 to 29. 
 
 
Table 26. Search strategy for MEDLINE 
  
Term Group # Search terms Results 
Disease area 1 heart arrest/ or death, 
sudden, cardiac/ or 
out-of-hospital cardiac 
arrest/ 
7914 
 2 ((Sudden adj2 death) 
or (cardiac arrest or 
cardiac death)).tw,kw. 
12106 
 3 1 or 2 14297 
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Population 4 (adolescen* or young* 
or student* or athlet* 
or soccer or 
football*).tw,kw. 
176412 
 5 exp adolescent/ or 
exp adult/ or exp 
Young Adult/ or exp 
child/ 
1141191 
 6 4 or 5 1186936 
Intervention 7 Mass Screening/ 12147 
 8 screen*.tw,kw. 121178 
 9 7 or 8 123570 
Study design 10 (randomized 
controlled trial or 
controlled clinical 
trial).pt. 
87688 
 11 meta-analysis.pt. 39519 
 12 exp cohort studies/ or 
longitudinal studies/ or 
follow-up studies/ or 
prospective studies/ 
384772 
 13 (random* or blind* or 
trial or cohort or 
longitudinal or 
prospective* or 
observational or 
registry or systematic 
review or meta-
analysis).tw,kw. 
493142 
 14 10 or 11 or 12 or 13 699524 
 15 3 and 6 and 9 and 14 233 
 16 3 and 9 672 
 17 2 and 14 5730 
 18 3 and 6 8800 
 19 3 and 6 and 9 534 
Limiters 20 limit 19 to (english 
language and 
humans) 
500 
 21 (letter or editorial or 
comment or case 
reports).pt. 
446948 
 22 20 not 21 429 
 23 limit 22 to yr="2014 -
Current" 
429 
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Table 27. Search strategy for MEDLINE(R) In-Process & Other Non-Indexed Citations, 
MEDLINE(R) Epub Ahead of Print 
 
Term Group # Search terms Results 
Disease area 1 heart arrest/ or death, 
sudden, cardiac/ or 
out-of-hospital cardiac 
arrest/ 
0 
 2 ((Sudden adj2 death) 
or (cardiac arrest or 
cardiac death)).tw,kw. 
8221 
 3 1 or 2 8221 
Population 4 (adolescen* or young* 
or student* or athlet* 
or soccer or 
football*).tw,kw. 
146874 
 5 exp adolescent/ or 
exp adult/ or exp 
Young Adult/ or exp 
child/ 
1 
 6 4 or 5 146875 
Intervention 7 Mass Screening/ 0 
 8 screen*.tw,kw. 89637 
 9 7 or 8 89637 
Study design 10 (randomized 
controlled trial or 
controlled clinical 
trial).pt. 
298 
 11 meta-analysis.pt. 37 
 12 exp cohort studies/ or 
longitudinal studies/ or 
follow-up studies/ or 
prospective studies/ 
0 
 13 (random* or blind* or 
trial or cohort or 
longitudinal or 
prospective* or 
observational or 
registry or systematic 
review or meta-
analysis).tw,kw. 
362146 
 14 10 or 11 or 12 or 13 362170 
 15 3 and 6 and 9 and 14 24 
 16 3 and 9 357 
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 17 2 and 14 2222 
 18 3 and 6 893 
 19 3 and 6 and 9 118 
Limiters 20 limit 19 to (english 
language and 
humans) 
114 
 21 limit 20 to yr="2014 -
Current" 
78 
 
 
Table 28. Search strategy for EMBASE 
  
Term Group # Search terms Results 
Disease area 1 heart arrest/ or death, 
sudden, cardiac/ or 
out-of-hospital cardiac 
arrest/ 
65256 
 2 ((Sudden adj2 death) 
or (cardiac arrest or 
cardiac death)).tw,kw. 
115068 
 3 1 or 2 141108 
Intervention 4 exp screening/ 603927 
 5 screen*.tw,kw. 908660 
 6 4 or 5 1137299 
Limiters 7 (letter or editorial).pt. 1593651 
 8 case report/ 2204788 
 9 conference 
abstract.pt. 
3217669 
 10 7 or 8 or 9 6682238 
 11 3 and 6 6981 
 12 11 not 10 3854 
 13 limit 12 to (human and 
english language and 
yr="2014 -Current") 
1313 
 
 
Table 29. Search strategy for the Cochrane Library Databases (Searched via the Wiley 
Online platform) 
Term Group # Search terms Results 
 1 ((sudden near/2 
death) OR “cardiac 
death” OR “cardiac 
213 
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arrest) AND screen* 
in Title Abstract 
Keyword  
 
 
 
Results were imported into EndNote and de-duplicated. 
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Appendix 8 — Included and excluded studies 
(Question 3) 
PRISMA flowchart 
Figure 3 summarises the volume of publications included and excluded at each stage of the 
review. No publications were found that were relevant to question 3. Reasons for non-
inclusion of studies are summarised in the PRISMA flowchart.  
 
Figure 3: Summary of publications included and excluded at each stage for question 3 
 
 
Records identified through 
database searches 
2033 
Titles and abstracts reviewed 
against eligibility criteria 
1402 
Duplicates 
631 
Records excluded after title/abstract 
review 
1252 
Full-text articles reviewed against 
eligibility criteria 
150 Records excluded after full-text review 
150 
Primary research with no comparator group 
(n=105) 
Commentary/ guideline statement (n=37) 
Abstract/ letter/ case report (n=3) 
News article (n=3) 
Not English language (n=1) 
 
Articles initially included in review 
0 
Articles selected for extraction and 
data synthesis 
0 
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Publications included after review of full-text articles 
No publications were included after review of full-texts.  
 
Studies were prioritised for extraction and data synthesis. It was planned a priori that the 
following approach would be taken to prioritise studies for extraction:  
1. Systematic reviews and meta-analyses would be considered the highest quality of evidence if 
any were found.  
2. Studies would be prioritised if they considered a UK population, followed by studies from 
Western populations analogous to the UK. 
 
Of the 150 publications included after the review of titles and abstracts, 150 were ultimately 
judged not to be relevant to this review. A list of the 150 full-text papers with reasons for 
exclusion is available from the UK NSC.  
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Appendix 9 – UK NSC reporting checklist for evidence 
summaries 
All items on the UK NSC Reporting Checklist for Evidence Summaries have been addressed in this report. A summary of the 
checklist, along with the page or pages where each item can be found in this report, is presented in table 30.  
 
Table 30. UK NSC reporting checklist for evidence summaries 
 Section Item Page no. 
1. TITLE AND SUMMARIES 
1.1 Title sheet Identify the review as a UK NSC evidence summary. Title page 
1.2 Plain English 
summary 
Plain English description of the executive summary. 5-6 
1.3 Executive 
summary 
Structured overview of the whole report. To include: 
the purpose/aim of the review; background; previous 
recommendations; findings and gaps in the evidence; 
recommendations on the screening that can or cannot 
be made on the basis of the review. 
7-11 
2. INTRODUCTION AND APPROACH 
2.1 Background 
and objectives 
Background – Current policy context and rationale for 
the current review – for example, reference to details 
of previous reviews, basis for current recommendation, 
recommendations made, gaps identified, drivers for 
new reviews 
Objectives – What are the questions the current 
evidence summary intends to answer? – statement of 
the key questions for the current evidence summary, 
criteria they address, and number of studies included 
per question, description of the overall results of the 
literature search. 
12-19 
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Method – briefly outline the rapid review methods 
used. 
2.2 Eligibility for 
inclusion in the 
review 
State all criteria for inclusion and exclusion of studies 
to the review clearly (PICO, dates, language, study 
type, publication type, publication status etc.) To be 
decided a priori. 
20-21 
2.3 Appraisal for 
quality/risk of 
bias tool 
Details of tool/checklist used to assess quality, e.g. 
QUADAS 2, CASP, SIGN, AMSTAR.  
22 
3. SEARCH STRATEGY AND STUDY SELECTION (FOR EACH KEY QUESTION) 
3.1 Databases/ 
sources 
searched 
Give details of all databases searched (including 
platform/interface and coverage dates) and date of 
final search. 
22 
3.2 Search 
strategy and 
results 
Present the full search strategy for at least one 
database (usually a version of Medline), including 
limits and search filters if used. 
Provide details of the total number of (results from 
each database searched), number of duplicates 
removed, and the final number of unique records to 
consider for inclusion. 
48-53, 60-69, 79-84 
3.3 Study 
selection 
State the process for selecting studies – inclusion and 
exclusion criteria, number of studies screened by 
title/abstract and full text, number of reviewers, any 
cross checking carried out. 
19 
4. STUDY LEVEL REPORTING OF RESULTS (FOR EACH KEY QUESTION) 
4.1 Study level 
reporting, 
results and 
risk of bias 
assessment  
For each study, produce a table that includes the full 
citation and a summary of the data relevant to the 
question (for example, study size, PICO, follow-up 
period, outcomes reported, statistical analyses etc.). 
Provide a simple summary of key measures, effect 
estimates and confidence intervals for each study 
where available. 
For each study, present the results of any assessment 
of quality/risk of bias. 
Study level reporting: 55-58, 71-77 
Quality assessment: 59,78 
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4.2 Additional 
analyses 
Describe additional analyses (for example, sensitivity, 
specificity, PPV, etc.) carried out by the reviewer. 
55-58, 71-77 
5. QUESTION LEVEL SYNTHESIS 
5.1 Description of 
the evidence  
For each question, give numbers of studies screened, 
assessed for eligibility, and included in the review, with 
summary reasons for exclusion. 
24-25, 33-34, 41 
5.2 Combining 
and presenting 
the findings 
Provide a balanced discussion of the body of evidence 
which avoids over reliance on one study or set of 
studies.  Consideration of four components should 
inform the reviewer’s judgement on whether the 
criterion is ‘met’, ‘not met’ or ‘uncertain’: quantity; 
quality; applicability and consistency. 
25-30, 34-38, 41-43 
5.3 Summary of 
findings 
Provide a description of the evidence reviewed and 
included for each question, with reference to their 
eligibility for inclusion. 
Summarise the main findings including the quality/risk 
of bias issues for each question. 
Have the criteria addressed been ‘met’, ‘not met’ or 
‘uncertain’? 
31, 39, 43-44 
6. REVIEW SUMMARY 
6.1 Conclusions 
and 
implications for 
policy 
Do findings indicate whether screening should be 
recommended? 
Is further work warranted? 
Are there gaps in the evidence highlighted by the 
review? 
45-47 
6.2 Limitations Discuss limitations of the available evidence and of the 
review methodology if relevant. 
47 
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